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Chapter 1. Introduction and literature review.
1.1 Overview
Recent developments of novel drug delivery systems are driven by the
requirements that target specific disease, maximize therapeutic efficacy while
minimizing side effects4-5. Among various therapeutics, a large portion of the drug
molecules exhibit physicochemical drawbacks such as poor solubility and
bioavailability, short circulation half-lives and nonspecific distribution that limited
their clinical applications6-7. To balance the effect of these limitations, drugs are
administrated usually at high treating frequencies or at high doses. This, however,
leads to adverse side effects or induces autoimmune reactions5, 8-10. One potential
approach to address these issues is to incorporate therapeutic drugs in to a
tailored delivery matrix, which controls the dosage, duration, and distribution of the
drug molecules after administration. For systemic administration, the delivery
system increases the circulating half-life and accumulation in target tissues. For
drugs administrated locally, the delivery vehicles intensively retain at the local site
to prolong the retention time. These attributes potentially enhance the performance
as well as reduce dosing frequency or concentration, which ultimately lead to
increased patient compliance7, 9, 11-13.
While existing drug delivery systems (e.g., liposomes) have fulfilled some
needs in the field, it remains challenging to design drug carriers which meet all the
criteria for delivery

14-16.

Possible loading efficiency, stability, toxicity and

immunogenicity issues greatly restrict the clinical applications of some of the
delivery systems in the short-term. An emerging strategy to overcome the above
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limitations is the design of drug amphiphiles which have the potential for selfdelivery. Self-delivery drugs 17-20 eliminates the need for external delivery systems.
A typical drug amphiphile21-23 can be divided into three distinct segments: a
pharmaceutical payload, a linker, and a chemical modification which renders the
whole amphipathicity (Figure 1.1.1A). Drug amphiphiles can be synthesized by
amphiphilic modification which alters the drug molecule’s physicochemical
properties and targets disease sites through several mechanisms. Because a
range of amphiphiles with great structural diversity are available for conjugation,
the physicochemical properties of a particular drug can be fine-tuned to achieve
desired characteristics such as solubility, stability, biodistribution, membrane
permeability and intracellular accumulation (Figure 1.1.1B). Tailoring the drug
amphiphiles’ structure and/or hydrophilic/lipophilic balance

24

leads to different

interactions with biological surrounding environment after administration. For
example, drug amphiphiles21 with appropriate HLB are capable of self-assembling
into stable supramolecular nanostructures under physiological conditions.
Compared to soluble drugs, these self-assembled drug nanostructures have
demonstrated to be superior in protecting labile drugs from degradation, controlling
the release of drugs, as well as site-specific drug accumulation. In general, drugs
delivered by nanoparticles exhibit reduced toxicity while maintaining or enhancing
the therapeutic effects. On the other hand, drug amphiphiles can be engineered to
bind plasma proteins (e.g., albumin or lipoprotein)22-23. Endogenous proteins are
natural carriers which are known to have long circulation half-life and improved
site-specific targeting. For example, drugs that bind to albumin accumulate in solid
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tumors by the enhanced permeation and retention (EPR) effects and more
importantly, by elevated metabolic activities in tumor in response to the need for
amino acids and energy

25-27.

Protein binding has also been used for lymphatic

targeting: following subcutaneous injection, vaccinal amphiphiles transport through
binding to the albumin and accumulate in the draining lymph nodes. Understanding
and controlling the molecular interactions between plasma proteins and drugs in a
complex biological environment is the key to harness this endogenous pathway for
targeted drug/vaccine delivery. Finally, the interplay between the drug amphiphiles
and biological membranes/or membrane transporter proteins/enzymes is known
to enhance the membrane permeability, which allows the crossing of critical
barriers such as blood-brain barriers, intestinal absorption barriers and specific
targeting at the cellular or intracellular level.
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Figure 1.1.1 Improving drug delivery by amphiphilic drug conjugate. (A)
Schematic illustration of the design of drug amphiphiles. A typical drug amphiphile
can be divided into three individual fractions: a pharmaceutical payload, a linker,
and a chemical modification which renders the drug amphiphilic. (B) The
interactions between drug amphiphiles and their biological surroundings can be
controlled by molecular engineering which governs the drug molecules’
physicochemical properties.
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1.2 The design principles of self-delivery drug amphiphiles.
For a long period of time, amphiphilic modification has been harnessed to
improve the biological activity of the parent compounds, providing decades of
referential experience to guide the current designs. For example, lipid-nucleoside
conjugates (nucleolipids) have been used since the 1970s to overcome drug
resistance.28 Generally, the novel amphiphilic modification provides superior
pharmacological properties compared to the parent compounds, including
improved oral bioavailability, increased stability and circulating half-life, facilitated
targeting at the organ, cellular and subcellular levels. The past decade has seen
tremendous progress in the exploration of amphiphilic modification to improve both
efficacy and safety of drugs. New drug amphiphiles are emerging as paradigms to
guide the rational design for therapeutic applications, some of which are
summarized in the following discussion.
1.2.1 Amphiphilic drug modification: conjugation strategies and types of
linkers.
Depending on the hydrophobicity of the drug, a hydrophobic or hydrophilic
modification is selected to be employed for the conjugation. The pharmaceutical
payload must contain reactive group(s) for covalent conjugation. There are a
variety of conjugation strategies available, including the formation of ester bond,
amide bond, thiol-ene reaction, azide-alkyne click reaction, bioreducible disulfide,
and many others. 29-30 The conjugation can form drug amphiphiles with cleavable
or non-cleavable linkage. Although non-cleavable linkers have the advantage of
increased plasma stability and reduced off-target toxicity, non-cleavable drug
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conjugation might compromise the performance by altering the binding affinity or
intrinsic activity of the drug. Recently, the use of stimuli-responsive linkages
designed for the traceless release of drugs from their conjugates has gained
significant attention.31-32 In these cases, payloads are released upon linker
cleavage in responsive to the environmental signals at the disease areas to
achieve spatiotemporal drug control and maximal drug efficacy. A large variety of
environmental signals such as biological, physical, or chemical stimuli and the
corresponding chemical linkers have been extensively explored in the past. 31-32 In
many cases, conjugation to cleavable linkers produces prodrugs that are inactive
before drug release. However, the choice of conjugation strategies for a specific
payload depends on the availability of appropriate functional groups on drug for
coupling, the metabolic pathways of the drug for in vivo stability, as well as the
requirement for drug release for maximal therapeutic potency. Importantly, the
functions of the linker molecules extend beyond payload connection and controlled
release.33-37 As demonstrated in previous examples, an appropriately designed
linker is also critical to the overall physicochemical properties of the whole
conjugate, which controls the stability of self-assembled supramolecular structure,
the ability for plasma protein binding, and cell membrane interactions.34-37 For
example, in a complexed biological environment, the molecular weight of
polyethyleleglycol (PEG) in a diacyl lipid-PEG-peptide conjugate controls the
dedicate balance between an albumin-binding state and a membrane insertion
state.35 In the late case where the payload needs to be anchored on the membrane
surface, a relative long, flexible linker enables the payload to extend from the cell
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surface, minimizing the potential steric hindrance which affects the receptor-ligand
interaction.36
1.2.2

Amphiphilic

modification

enhances

circulation

half-life

and

tissue/organ targeting.
To achieve a high therapeutic index, drug is expected to accomplish
sufficient circulation time in blood for target exposure, and site-specific
accumulation following parenteral administration. Due to their low molecular
weights, small molecule drugs are rapidly cleared from the blood through renal
excretion. Additionally, many biotherapeutics (peptides, oligonucleotides) have
extremely short in vivo half-life due to their susceptibility to enzymatic degradation.
Amphiphilic modification can prolong the plasma half-life of the drug by several
distinct mechanisms. First, drug amphiphiles self-assemble into nanostructures
with different shapes and sizes. Molecular assemblies with a hydrodynamic
diameter greater than 5.5 nm exceed the renal filtration threshold and prevent the
rapid clearance via renal filtration and urinary excretion.38-39 Therefore, selfassembled drug amphiphiles are larger in size than monomeric drug alone, making
them more likely to have long blood circulation time. Second, amphiphilic
modification and molecular self-assembling protect the vulnerable drugs from
enzymatic degradation, improving the drug molecules’ stability in circulation. The
third mechanism is that certain drug amphiphiles are designed to bind tightly to
serum albumin or lipoprotein. Albumin has a hydrodynamic size of approximately
7 nm and is one of the plentiful protein in the blood and interstitial fluids. 40-41
Compared to molecular drug alone, albumin binding forms an albumin-drug
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complex with greater size and prevents the drug from renal clearance. Importantly,
albumin has an extraordinarily long circulation half-life (~19 days) in human due to
its unique neonatal Fc receptor-driven recycling pathway (avoid lysosomal
degradation).42 Similarly, lipoproteins are natural nanoparticles which have long
residence time in the circulation.42 Therefore, drug amphiphiles transportation via
the albumin or lipoproteins is an effective approach to extend the circulation time
in vivo.
Apart from increasing the circulating half-life, amphiphilic modification can
affect the delivery of drugs to the target sites. Increasing the molecular sizes by
self-assembling or protein-binding is known to preferentially accumulate the drug
in tumor tissue or inflammatory site via EPR effect.43 This passive targeting
approach (EPR) is the primary mechanism of the majority of current nanomedicine
for the treatment of solid tumors. In addition to passive targeting, it is known that
under conditions of cellular stress, albumin is taken up as a source of amino acid
and energy due to increased catabolic activities at disease sites. Although the
exact cellular receptors for albumin remain to be identified, albumin-based selfdelivery drugs have been used to target solid tumor as well as inflammatory
conditions such as rheumatoid arthritis.44-45 Finally, self-delivery amphiphilic
vaccines which bind to albumin accumulated in the antigen presenting cells (APCs)
in the lymph gland after subcutaneous injection.35 In contrast to unmodified
vaccines, which rapidly diffuse into blood circulation due to their small molecular
weights, amphiphilic vaccines bind to albumin, drain to the lymphatic capillaries
and filtered by APCs in the lymph nodes. Because of its ability to efficiently deliver
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vaccine components to lymph node, this novel amphiphilic vaccine approach
elicited a dramatic increase in antigen-specific T cells compared to unmodified
vaccines. 35
1.2.3 Amphiphilic modification improves oral bioavailability.
Oral administration of therapeutic agents is highly preferred because of the
convenience

with

non-invasive

and

self-administration.

However,

drugs

administered orally must overcome a series of harsh environments and absorption
barriers in the gastrointestinal tract. For example, the numerous enzymes and
acidic pH in the digestive tract are designed to break down molecules including
drugs before they can be absorbed and enter the bloodstream. Many drug
compounds do not have the physicochemical characteristics required for oral
administration. Amphiphilic modification of drugs can help improving oral delivery
by maintaining the drug molecules’ structure integrity in gastric environment and
increasing intestinal permeability.46 Depending on their distribution and
metabolism, orally administered drug molecules can enter the systemic circulation
through the intestinal lymphatic system or absorption in portal blood capillaries
after intestinal epithelium permeation.46-47 In both routes, drugs must cross the
epithelium barrier, a single layer of cells with selective permeability for dietary
nutrients and other substances. In this process, membrane permeation is a quite
complex process and has encompassed a wide range of passive and active
mechanisms. However, drug lipophilicity plays a dominate role in the absorptive
membrane permeability and subsequent blood absorption. 48-49 Molecules with
higher lipophilicity generally exhibit better permeability than hydrophilic drugs.48-49
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Current methods for addressing the permeability associated with hydrophilic drugs
have focused on chemical modifications which increase the lipophilicity of drugs.
Intestinal lymphatic absorption and transport is a unique pathway for oral drugs to
enter systemic circulation.50-51 The mammalian intestine is intensively perfused
with lymphatic capillaries, which absorb dietary lipids and vitamins from the
gastrointestinal tract.50-51 In this pathway, orally administered lipids or lipophilic
drugs are transported to intestinal lymphatic system by associating with
lipoproteins. These lipoproteins associated drugs subsequently enter blood
circulation, thus avoiding the potential first-pass metabolism in the liver.50
Appropriate lipophilic modification on drug is essential to hijack this lymphatic
uptake pathway for oral drug delivery.
1.2.4 Amphiphilic modification overcomes blood-brain barrier.
Passing the blood-brain barrier (BBB) is one of the important steps for drug
to reach the brain following systemic administration. However, the BBB consists of
a monolayer of tightly packed endothelial cells expressing efflux transporter
proteins

(e.g.

P-glycoprotein,

Pgp),

blocking

most

drugs

administered

systematically from entering the brain and central nervous system.52-53 Although
transport across the endothelium by ligand-receptor binding is possible, passive
diffusion of the drug across brain endothelial cells remains the predominant
route.53 Structurally, many factors can affect the passive permeability of drugs
crossing BBB. Studies have shown that compounds with high lipophilicity (higher
Log P), less hydrogen bonds (< 8-10), and low molecular weight (<500) have better
permeability to BBB.53 Thus, amphiphilic modification which reduces Pgp protein
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efflux and increases lipophilicity will likely increase BBB permeation.54 It is
generally believed that plasma protein binding limits the diffusion of the drugs,
especially for drugs with high association rate

55

and low dissociation rate (Koff).56

However, several plasma proteins (e.g., transferrin and low density lipoproteins)
can penetrate BBB by receptor mediated transcytosis, a mechanism which has
been explored for enhancing BBB pemeability.49 Therefore, care should be taken
in terms of plasma protein binding when designing drug amphiphiles to cross BBB.
1.2.5 Amphiphilic modification facilitates drug uptake and targeting at
subcellular level.
In addition to the above extracellular barriers, targeted delivery of
therapeutics requires transportation across the cell membrane, and ultimately to a
defined subcellular structure. Several biological barriers must be permeated to
achieve efficient subcellular disposition. Amphiphilic modification has also been
explored to enhance the cellular uptake, to anchor the drug molecules on plasma
membrane, and to direct the drugs to specific subcellular compartments.
Amphiphilic especially lipophilic conjugation was reported to be used of as an
uptake enhancing approach for hydrophilic drugs.

57

This attribution heavily relies

on the hydrophobic interactions between the lipophilic moieties and cellular
membranes.58 Passive diffusion across membrane bilayers is the most important
permeability mechanism. The ability to associate and dissociate with the
hydrophobic membrane interior is one of the dominant parameters governing
transmembrane diffusion.58 While highly hydrophilic molecules fail to enter
membrane, extremely lipophilic molecules are trapped within the lipid bilayers and
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fail to diffuse out. Thus, balancing the hydrophobicity of drug amphiphiles is critical
in transmembrane diffusion. In addition to simple diffusion, lipid-based amphiphiles
have been shown to spontaneous insert their hydrophobic lipid tail into the lipid
bilayer of membrane as a precursor for subsequent cellular uptake.59-60 This
mechanism enables the membrane translocation of otherwise impermeable
molecules. In contrast to direct diffusion, membrane inserted drug amphiphiles
either remain in the membranes (plasma and intracellular membranes) or release
the drug payload by appropriate mechanisms. The final mechanism associated
with enhanced cellular uptake of drug amphiphiles is the receptor-mediated uptake.
Lipoprotein- or albumin-bound drug amphiphiles are recognized by endocytic
receptors on the plasma membrane, followed by rapid internalization.

61-62

Transmembrane protein receptors are important drug targets as cells use
them for signal transduction, molecules transport, and cell-cell interactions.
Anchoring drug amphiphiles on the cell surface has been harnessed to enhance
the affinity and stability of ligand-receptor binding.63-65 These membrane anchored
amphiphiles firmly anchor the drug molecules on the surface of the cells,
increasing the local ligand concentrations around the receptors by restricting the
ligand diffusion. Thanks to the unique bi-valent interactions between cell surface
receptor and ligand, both binding affinity and stability can usually be improved. 63
Besides being an appropriate membrane targeting approach, recent
advances have identified amphiphilic drug modification as a novel strategy for
subcellular targeting of drugs.66 The exact mechanisms of how amphiphilic
modification leads to subcellular organelle accumulation remain poorly established,
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but it is believed that the overall physicochemical properties and ligand-receptor
interactions govern the intracellular sorting and trafficking pathways. 66 Therefore,
amphiphilic modification can be utilized to enhance or reroute the drug molecules
to specific organelles. For example, amphiphilic modification is an effective way
for cytosolic targeting of small interfering RNAs (siRNA).67-69 Lipophilic ligands
modified siRNA associate with high density lipoproteins and cross the membrane
directly into cytoplasm via non-endocytotic pathway mediated by the scavenger
receptor BI.70 A wide range of lipophilic moieties including cholesterol, fatty acids,
steroids were used for siRNA conjugation and some of them have reached clinical
stage.69 Amphiphilic modification has also been utilized for the endosomal
entrapment in drug delivery. Due to its high affinity toward membrane bilayer,
diacyl lipid-immunostimulatory oligonucleotide conjugates were designed to target
Toll-like receptor (TLR) 9, which are exclusively expressed within the endosomal
compartments of antigen presenting cells.35 The enhanced cellular uptake and
intracellular targeting by amphiphilic modification have been utilized to overcome
the

drug-resistance,

one

of

the

major

challenges

in

current

cancer

chemotherapy.71-75 This is achieved by amphiphilic conjugation which alters the
internalization pathways, or delivers and anchors the drug to intracellular
organelles where the P-glycoprotein efflux pump cannot access.71, 75
1.3 Clinical and preclinical examples of drug amphiphiles.
1.3.1 Amphiphilic oligonucleotides (ODNs).
The albumin-hitchhiking approach has been recently applied to deliver
immunostimulatory

oligonucleotides

(ODNs)

to

the

lymph

nodes

after
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subcutaneous injection.35,

76-77

Liu et.al. conjugated diacyl lipid to the single-

stranded oligonucleotides CpG DNA (Figure 1.3.1.1), consisted of unmethylated
cytosine-guanine motifs that bind Toll-like receptor-9 (TLR-9) and do the duty for
potent immunological adjuvants.35 Amphiphilic CpG accumulates in the antigen
presenting cells in the lymph nodes by transporting and trafficking by the help of
endogenous albumin protein. Albumin binding prevents CpG ODN from rapidly
spreading into the blood circulation and re-target them to the lymphatics and
draining lymph nodes, where they are filtered by various antigen presenting cells.
Interestingly, both the molecular weight of the diacyl lipid and ODN affect the
albumin binding and subsequent lymph node accumulation: longer diacyl lipids
than sixteen carbons, which exhibit a high affinity for albumin showed intense
accumulation in LN. At the same time, shorter diacyl lipids than fourteen carbons
with low affinity exhibited markedly reduced retentions.35 The optimal length of
ODN was determined to be 15-30 nucleotides.35 This vaccine approach elicited
extensive antigen-specific T cell priming and improved anti-tumor proliferation
effects. In addition to albumin-binding, diacyl lipid modification of ODNs provides
a consolidating and embedding pathway for intercellular entrance by interacting
with plasma membrane. Due to the inherent affinity toward membrane bilayers,
lipid-ODNs are able to spontaneously insert onto the surface of the membrane. 34,
37

This property has been utilized for localized ODN delivery. In an attempt to

augment the anti-tumor immune response, Liu et.al. used diacyl lipid conjugated
immune stimulatory ODNs for in situ tumor cell modification (Figure 1.3.1.1).37
Intratumoral injected diacyl lipid modified CpG DNA spontaneously insert into the
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plasma membrane of tumor cells, leading to significantly increased local retention
time in tumor. This approach also promotes the association of immune adjuvant
(CpG) with tumor antigens. In situ stimulation of malignant cells will be favourable
for the local activation of antigen presenting cells such as dendritic cells
responding to apoptotic tumor cells.37 Finally, diacyl lipid-ODNs were dominantly
accumulated in the endosomes, where TLR-9 are expressed. In a murine
melanoma tumor model, cell membrane anchored CpG ODNs with nucleaseresistant phosphorothioate backbone displayed markedly enhanced immune costimulatory activity and improved anti-tumor efficacy compared to soluble CpG.37

Figure 1.3.1.1 Representative examples of oligonucleotide amphiphiles.
Amphiphilic immunostimulatory oligonucleotide equilibrates between membrane
insertion state and albumin binding state and can be used to directly label tumor
cells (intratumoral injection) or target draining lymph nodes (subcutaneous
injection).
1.3.2 Amphiphilic peptides.
Peptide amphiphiles

47

are amphiphilic molecules that contain bioactive

peptides. PAs can be synthesized by linking amino acids into hydrophilic and
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hydrophobic domains, or by conjugating oligopeptide to hydrophobic hydrocarbon
chain (lipopeptide).78-80 Due to their amphiphilic properties, PAs self-assemble into
nanostructures under certain conditions. The self-assembly of PAs is believed to
be driven by a combination of molecular interactions such as hydrogen bonding,
hydrophobic interactions, van der Waals force, and electrostatic interactions. 80-81
Combining the amphiphilic features with the bioactive peptides, PAs have been
shown great promise in biomedical applications and can be utilized to act as antipathogenic agents to treat infections, as vaccines/immunotherapy agents or as
cosmeceuticals.79
The antibacterial, antifungal and antiviral activity of naturally expressed PAs
from bacteria were extensively studied in the past.82 The first PA-based antibiotic,
Cubicin® (Daptomycin, figure 1.3.2.1A), was approved for the treatment of
complicated skin infections by Food and Drug Administration (FDA) in 2003 in
USA.83 Daptomycin is an amphiphilic peptide and consists of cyclic 13 amino acids
peptide linked to a decanoyl lipid chain. Despite years of study, its exact molecular
mechanism of activity remains unclear.84 Accumulated evidences suggest that by
inserting of its hydrophobic decanoyl chain into bacterial membrane, daptomycin
causes membrane permeabilization and potassium ions outflow, leading to rapid
bacteria cell death.84 The formation of spherical micelles by daptomycin has been
proposed to facilitate bacterial-targeted delivery.85 However, studies also shown
that more than 90% of the total amount of daptomycin in blood is proteinbounded,86-87 which in turn, may affect its antibacterial activity, as demonstrated in
protein-free media.88 Yet these in vitro protein binding studies failed to predict

17

clinical efficacy of daptomycin, suggesting other important characteristics, such as
favorite pharmacokinetics are of vital clinical importance to the success of antibiotic
therapy. Several other PAs such as caspofungin, anidulafungin, and micafungin
have been approved as antifungal antibiotics.89
PAs are also designed to anchor peptide ligands on the surface of cell
membrane, creating a cooperative receptor-ligand binding and increasing the local
ligand concentrations around receptors. Conjugating cholesterol to HIV fusion
inhibitory peptide (C34) creates a peptide amphiphile capable of member
insertion.90-91 The amphiphilic modification anchored C34 on the cholesterolenriched lipid rafts, resulting in dramatically enhanced potency in terms of HIV
inhibition (Figure 1.3.2.1B).90-91 Importantly, anchoring C34 peptide on cell surface
also enhance the peptide’s stability, as the antiviral activity appeared to be
persistent following extensive wash.90 Similar lipid peptide-based HIV fusion
inhibitors were reported.91-92 The dramatically enhanced inhibitory potency and
stability, combined with the >300-fold increase in plasma concentration, make this
amphiphilic strategy attractive in blocking many other virus entry during infections.
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Figure 1.3.2.1. Examples of peptide amphiphiles. (A) Molecular structure of
Daptomycin. (B) Model of action of cholesterol-C34 peptide in HIV fusion inhibition.
Cholesterol-C34 anchors on the surface of host cells and increases both the affinity
and duration of ligand-receptor interactions. (C) Amphiphilic peptide epitopes selfassemble into cylindrical micelles and facilitate the uptake of antigen presenting
cells. (D) Structure of long-acting insulin detemir (Levemir). Insulin is modified with
myristic acid at the lysine amino acid at position B29. This modification causes
protein self-association as well as albumin protein binding, which prolongs the
duration of action.
PAs are also extensively explored in vaccine applications primarily due to
their abilities to self-assemble into nano-sized structures. The peptide epitopes
displayed on the surface of nano-structures closely mimic the highly repetitive
antigens on the pathogen surface, which are believed to be critical in B cell
receptor clustering.93 In addition to directly activate B cells, the PA-based selfassembled nano-vaccines have been frequently used to target antigen presenting
cells (APCs).94 This is achieved by two distinct pathways: first, nano-vaccine
formulations promote lymph nodes draining through lymphatic capillaries. 51,

93

Unlike small molecule epitopes, which quickly diffuse into blood circulation after
subcutaneous or intramuscular injection, nano-vaccines preferentially drain to the
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lymph nodes. Alternatively, the physicochemical properties of nano-vaccines also
facilitate the uptake by APCs.95 Because of this targeting mechanism, a variety of
fully synthetic PAs with both B-cell and T-cell epitopes have been synthesized and
tested. The first example of PAs in vaccine application was reported in 1984. Hopp
and co-workers pioneeringly synthesized PAs by conjugating dipalmitoyl-lysine
moiety to a peptide bearing hepatitis virus epitopes.96 The amphiphilic modification
significantly improved the production of antibodies against hepatitis surface
antigen.96 Tirrell and coworkers conjugated dialkyl lipid with two palmitic chains to
a series of peptide containing B cell or T cell epitopes (Figure 1.3.2.1C).97-98 These
lipid conjugated peptides self-assembled into cylindrical micelles and elicited
potent humoral and cellular responses in mice. In many of these examples, the
synthetic assemblies are able to elicit potent immune responses without the need
for additional molecular adjuvants, which make them attractive in the design of
safe vaccines.
In addition to the self-assemble property, PAs can be carefully engineered
to bind albumin protein. Insulin is widely used to treat diabetes mellitus type 1.
However, insulin is quickly degraded (half-life 4-6 minutes) after its release into
blood. Insulin detemir (Levemir®) is a long-lasting insulin analogue in which
myristic acid is conjugated to the B29 lysine (Figure 1.3.2.1D). It binds to albumin
in the blood and lasts 18 to 23 hours after injection.99 Insulin degludec (Tresiba®)
is ultralong-acting insulin (up to 42 hours) in which a longer fatty acid
(hexadecanedioic acid) was used for B29 lysine conjugation.100 Increasing the
hydrophobicity of the lipid results in the formation of self-assembled multi-
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hexamers in subcutaneous tissues which prolong the release of insulin into blood
circulation.100 Similarly, Liraglutide (Victoza®) is a fatty acid modified Glucagon-like
peptide-1 (GLP-1) agonist used to treat type 2 diabetes.101 Endogenous GLP-1
has an extremely short half-life in blood (1.5-2 minutes). However, attaching an
albumin-binding fatty acid dramatically prolongs its circulation life. Albumin-binding
also facilitate therapeutic peptide transport to lymph nodes. 51 Instead of forming
the micelle structure, peptide antigens conjugated to a long chain (>16 carbons)
diacyl phospholipid via a long PEG (Mw > 2000) linker preferentially bind to
albumin after s.c. injection.35 This new lymphatic system targeting approach
dramatically improved the peptide vaccine’s efficacy and safety.
Lipopeptides derived from microbial origin are important molecular
adjuvants which potently stimulate the innate immune system via Toll-like
receptors. For example, bacterial lipoprotein derivatives that contain dipalmitoylS-glyceryl cysteine (Pam2Cys) or tripalmitoyl-S-glyceryl cysteine (Pam3Cys) can
trigger TLR1/2 and TLR2/6 activation.102 Covalently conjugating low molecular
weight haptens, B cell and T cell epitopes to lipopeptide adjuvants has been shown
to elicit improved humoral and cellular immune responses in experimental animals
and human clinical trials, providing protections against infection and cancer. In
1998, FDA approved LYMErix™ as a general vaccine for Lyme disease.
LYMErix™ is Pam3Cys linked to out surface protein A (OspA) of Borrelia
burgdorferi. Despite the fact that clinical trials in over 10906 individuals showed a
76% reduction in Lyme disease, with no significant adverse effects, LYMErix™
was withdrawn from market by the manufacturer due to press coverage of vaccine
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risks which led to poor market performance.103 In general, attaching fatty acids
such as palmitic acid (palmitoylation) to peptide epitopes enhances the
hydrophobicity of antigens, and contributes to their membrane interactions which
facilitate TLR engagement (TLR1/2 and TLR2/6 are surface TLRs).
1.3.3 Amphiphilic Small Molecular Drugs.
Amphiphilic modification of anti-cancer low-molecular-weight drugs which
enables self-delivery of drugs to tumor cells has attracted significant research
interests. Amphiphilic drugs conjugation leads to the formation of stable
supramolecular assemblies, which improves the stability, circulating time, and
tumor penetration/retention of parent drugs. For example, linear amphiphilic
polymer was conjugated to hydrophobic camptothecin (CPT) analog SN38. 104 The
amphiphilic modification leads to micelle forming PEG2000-SN38. Compared with
soluble SN38, micellar SN38 showed enhanced cytotoxicity in vitro and antitumor
efficacy in vivo.104 Similarly, Shen and coworkers conjugated oligomeric ethylene
glycol to one or two copies camptothecin. Instead of forming micelles, these
amphiphilic

camptothecins

formed

nanovesicles

due

to

the

reduced

hydrophilic/lipophilic balance.105 The vesicles can encapsulate other hydrophilic
drugs such as doxorubicin for combination therapy.105 The formation of nano-sized
nanoparticles (typically micelles) by linking multiple copies of drugs to PEGcontaining polymeric scaffolds is also extensively explored. In addition to PEG,
fully synthetic peptides have been used to aid the amphiphilic self-assembly. Cui
and coworkers conjugated hydrophilic peptides to camptothecin (Figure
1.3.3.1A).106 Besides the simply hydrophobic interactions, this design also takes
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advantages of the highly predictable self-assemble properties of peptides, by
which multiple molecular interactions including van der Waals forces, ionic bonds,
hydrogen bonds are involved in the self-assembly.80 The addition of a reducible
disulfide linker allows the release of CPT upon tumor cell uptake and internalization,
resulting greater cytotoxic effect in vitro.106

Figure 1.3.3.1. Example of small molecule drug amphiphiles. (A) molecular
structures and TEM images of self-assembling camptothecin and peptide
conjugates. (B) self-assembling irinotecan-chlorambucil drug-drug conjugate. (C)
Molecular structure and confocal image of mitochondria-targeting amphiphilic
doxorubicin.
Hydrophobic modification (typical lipid modification) on hydrophilic drugs
leads to the formation of nanostructures by self-aggregation. Conjugating
doxorubicin to squalene led to the formation of squalenoyl doxorubicin
nanoaggregations with a mean diameter of 130-nm.107 Compared to unmodified
doxorubicin, this simple conjugate dramatically improved the therapeutic anti-
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cancer efficacy in vivo. Similar amphiphilic lipid-drug conjugates are extensively
reviewed.75
An emerging new strategy in the design of self-delivery drugs is the
amphiphilic drug-drug conjugation. In this strategy, self-assemble amphiphiles
consisting of hydrophilic and hydrophobic drugs were conjugated. Huang and
coworkers covalently conjugated hydrophilic irinotecan and hydrophobic
chlorambucil (Ir-Cb) via a cleavable ester bond (Figure 1.3.3.1B).108 In aqueous
buffer Ir-Cb self-assembles into nanoparticles and facilitates the delivery to tumor.
Both irinotecan and chlorambucil were released from the prodrug due to hydrolysis
by intracellular esterases. Since then, different amphiphilic drug-drug conjugates
with self-assemble capacities have been designed.109 Targeting multiple anticancer drugs to tumor site synergize the cytotoxic effect and overcome the multiple
drug resistance, especially when drugs with different mechanisms of action were
used.
Intracellular organelle targeting by lipid-drug conjugates is a new, yet
exciting strategy to improve drug delivery. Lipids spread the entire cell, trafficking
from the cell surface to/ within the various organelle membranes where lipid
metabolism ocurrs. Increasing evidence demonstrated that internalized lipid-drug
conjugates were distributed to various subcellular organelles in a lipid- and/or drugspecific manner.110-111 By varying the lengths of acyl chain and altering the order
of domains, M Koivusalo and co-workers demonstrated the ordered-domain
sphingomyelins with long chain was observed in endosomes and then recycled to
the plasma membrane, while short-chain, disordered sphingomyelins were
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trapped in late endosomal compartments.110 Depending on the nature of the
amphiphilic modification, the small molecule chemotherapeutic drug doxorubicin
can be targeted to different intracellular locations. Maksimenko et al. conjugated
doxorubicin to squalene via a cleavable ester bond.107 Squalene-doxorubicin selfassembled into nanoassemblies of ~130-nm diameter, and efficiently deliver
doxorubicin to the nuclei, presumably by releasing the free drug after intracellular
entry. In a separate study, Xi et al. conjugated the amine group of doxorubicin to
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine

(DSPE)

linked

with

a

polyethylene glycol linker (amph-DOX, Figure 1.3.3.1D).74 Interestingly, this
simple molecular conjugate achieved high levels of tumor- and mitochondriaselective accumulation of doxorubicin. Although it is not clear how amphiphilic
modification impacts doxorubicin’s cellular uptake and intracellular trafficking, it is
concluded that amphiphilic modification altered the physicochemical properties of
doxorubicin, which in turn retargets it to mitochondria.74
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Chapter 2. Self-delivery of chemotherapeutic agents to tumor via ‘albuminhitchhiking’.
2.1 Introduction.
2.1.1 Albumin as a fatty acid transporter.
Fatty acids play critical roles as a source of biological supplement in
mammalian bodies and boundary of physiological membranes

1-112.

Due to low

solubility of fatty acids in blood plasma and interstitial fluid, albumin, a main
transporter, binds with FAs to increase their concentration in vascular bundle and
interstitial subdivision. As the most abundant plasma protein (35 - 50 g/L human
serum), albumin has a molecular weight of 66.5 kDa and a heart-shaped structure
which is folded from a single polypeptide chain.2 Interaction between fatty acids
and human serum albumin (HSA) was firstly reported in 1941. In this study, after
four-times’ crystallization, albumin was still observed to be yellow, a color from the
existing impurity of plasma dyestuffs, which was further recognized to be FA.113 In
the following years, several studies unveiled the binding properties of albumin to
FA. It is known that albumin protein comprises three homologous domains, each
containing two distinct subdomains. Curry and colleagues demonstrated plasma
albumin possessed seven FA-binding sites (FA1-FA7)

114-115,

which were

asymmetrically distribute throughout the albumin protein (Figure 2.1.1.1) 4-5. There
are seven bindings sites (FA1-7) lying in subdomain IB, subdomain IIIB, between
IA and IIA or IIA and IIB, and within subdomain IIIA and subdomain IIA. Among
these sites, FA4 and FA5 entirely located within domain III, which are highly
appealing to FAs allowing the lipid tail to bind in a nearly linear formation. Residues
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located outside of subdomain IIIA in FA4 will bind the carboxylate head-groups of
FAs through hydrogen force, whereas the lipid tail convolves into the hydrophobic
cuniculus throughout subdomain IIIA

113-114, 116.

FA5 resided in subdomain IIIB

provides spaces for the side-chains of residues (Tyr401 and Lys525) binding to
the carboxylate head-group of the FA, meanwhile methylene tail protrudes further
into the long linear cavity, resulting in a unique structure and a comprehensive view
of binding properties.

117

On the other hand, complexes with different parts such

as small molecules reveal the appearance of small sub-hole within this crevice 118.

Figure 2.1.1 Fatty acid (FA) binding sites in human serum albumin (HSA).4-5
2.1.2 Albumin as a drug carrier in cancer therapy.
Drugs administrated in various routine are transported by the blood or
interstitial fluid. They firstly encounter are not only the miscellaneous interstitial
compounds or originations and cellular components, but also a multitude of plasma
proteins. Plasma albumin has been emerged as a versatile protein carrier for
improving the pharmacokinetic profile and targeting of cancer drugs.
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Figure 2.1.2.1 Accumulation of the Evans blue in sarcoma180 tumors over
72 h.12
For all cancers, a common method of growth is to parasitize the hosts for
energy and nutrients

119,

not only a variety of small molecular nutrients such as

fatty acid and amino acids but also some large molecular proteins such as albumin.
Compared with normal tissue, tumors act as ‘nitrogen traps’ in protein metabolism
and uptake most of the proteins by pinocytosis

120-121.

Even under the stress of

starvation, there is no release of tumor proteins for the body.122 Seepy ciliary
vascular combined with a vacant or defective lymphatic drainage of solid tumor
also trap albumin in such tissues. Matsumura and Maeda firstly demonstrated that
Evans blue dye that had avidity to albumin accumulated in tumor after intravenous
injection. 21 After 6 hours, blue color from Evans blue dye was observed in the
tumor area in in preclinical models, which intensified over 72 hours (Figure
2.1.2.1).123 The tumoritropic accumulation of proteins with various molecular sizes
from 12 to 150 kDa were also explored. However, there was no significant
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differences observed between the uptake of albumin (MW 66.5 kDa) and
immunoglobulin (MW 150 kDa). They concluded that due to the tumoral
hypervasculature, macromolecules had an enhanced permeability and little
recovery through either blood vessels or lymphatic vessels. In addition, a certain
time of drug circulating in blood was also speculated to be the prerequisite for an
increased accumulation tumor uptake of the protein. Based on such reports,
macromolecules passively target tumor via enhanced permeability and retention
(EPR) are further developed.123 Tumor vessels are poorly aligned with endothelial
cells leading to the formation of wide fenestrations whose size are varies from 100
to 1200 nm in diameter124-125 Associating with tumor vascular fluid and components
transportation, macromolecules introduced as drug carriers having hydrodynamic
size between 2 nm to 10 nm in radius (e.g., serum albumin has a radius of 3.6 nm)
are permitted to spill over into tumor tissue instead of normal tissue. Thus,
macromolecules permeate through the impaired and defective blood vessels in
tumor tissue whereas healthy veins only grant small molecule flow across the
endothelial barrier. Another factor of the intensive uptake of large molecular weight
(> 40 kDa) components in tumor tissue is the reduced clearance 126. The
macromolecules are retained in the interstice of tumor tissue leading to a high
intratumor concentrations which is primarily caused by a lack of lymphatic drainage
in such defective lymphatic system. Hence, both an enhanced permeability and
retention (EPR) and reduced clearance effects of macromolecules are contributing
to the accumulation and retention of albumin in solid tumors.
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2.1.2.2 Drug delivery via albumin-hitchhiking.
Methotrexate-albumin conjugate (MTX-HSA) was one of albumin-based
drug delivery system evaluated in clinical studies127. Directly conjugating the MTX
to lysine residues of human serum albumin, discrepant antitumor proliferation
properties in Walker-256 carcinoma bearing rats were observed and only coupling
ratio close to one MTX to one albumin exhibited the high-level performance of
tumor specific accumulation comparative with unmodified albumin 128-129. A
prominent observation of this study was the remedial responses to MTX-HSA
therapy from three patients with kidney cancer or mesothelioma (one partial
response, two minor responses). However, no objective results were identified in
the following phase II study that 17 patients with metastatic kidney carcinoma 130.
Combinational therapy of MTX-HSA with another chemotherapy cisplatin was
conducted as the first line treatment to the carcinoma of urinary bladder in another
phase II study. Although obviously remissions were confirmed in seven patients,
there is no evidence that the clinical application of this therapy is being further
applied. 131
Kratz and co-workers modified the albumin conjugation methods of drug
derivatives and obtained high-purity drug albumin coupling components with a
constant drug coupling ratio. This approach set the breaking point of protein in
advance to reduce alteration in three-dimensional structure.

132

The resulting

conjugate was distinctly superior against murine kidney cancer compared to mice
treated with free doxorubicin at equitoxic dose

132.

Their further work stated a

prodrug concept that exploited endogenous albumin as a self-delivery platform by
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which the prodrug was designed to rapidly and specifically bond to circulating
plasma albumin after intravenous injection. The albumin/drug complex was
spontaneously generated and transported as the normal albumin in situ through
the vein 133-134. Employing endogenous albumin as a transporter can avoid possibly
immunogenicity from pathogenic albumin. In addition, there is a broad range of
drugs can be designed as albumin-binding drugs which are comparatively primitive
and inexpensive to develop in engineering. For example, acid-sensitive
doxorubicin prodrugs (DOXO-EMCH) was reported to follow such strategy and
showed dramatically improved antitumor efficacy in preclinical murine cancer
models132.
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2.2 Method.
2.2.1 Materials, cells and animals.
Doxorubicin hydrochloride salt was obtained from LC laboratories (Woburn,
MA).

1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine

(DSPE)

conjugated

polyethylene glycol (PEG 2000) with active succinimidyl ester (DSPE-PEG2000NHS) was purchased from Biochempeg scientific Inc (Watertown, MA).
Cholesterol polyethylene glycol (PEG 2000) NHS and DSPE-PEG2000-NHNH2
were ordered from Nanocs Inc (New York, NY). Triethylamine (TEA), Nhydroxylsuccinimide (NHS), bovine serum albumin (BSA), filipin (FLP), ethylisopropyl amiloride (EIPA) and sucrose were purchased from Sigma-Aldrich (St
Louis, MO). Alexa Fluor 660 NHS Ester (Succinimidyl Ester) was obtained from
Thermo Fisher Scientific (Waltham, MA). Cells were cultured in complete medium
(RPMI1640, 10% fetal bovine serum (Greiner Bio-one), 100 U/mL penicillin G
sodium and 100 μg/mL streptomycin (Pen/Strep). Mouse skin melanoma (B16F10)
cell line, mouse mammary carcinoma (4T1) cell lines were ordered from ATCC.
Animals were housed in the United States Department of Agriculture (USDA)inspected Wayne State University animal facility under federal, state, local and NIH
guidelines for animal care. Female C57BL/6 mice (5-8 weeks) were obtained from
the Jackson Laboratory.
2.2.2 Synthesis of amphiphilic doxorubicin and doxorubicin loaded micelles.
Doxorubicin hydrochloride (DOX, 5 mg, 8.6 mmol) were dissolved in 0.5 mL
dimethyl sulfoxide (DMSO) solvent and DSPE-PEG2000-NHS (38 mg, 5.7 mmol)
were added to 4.5 mL of the same solvent. These two solutions were
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homogeneously mixed with addition of 3 µL triethylamine (TEA). After stirred in the
dark at room temperature (RT) for 12 hours, most of the DMSO solvent was
removed in a stream of air for 72 h. The product residues were re-dissolved in 5
mL D.I water for high performance liquid chromatography (HPLC) purification.
Amphiphilic doxorubicin (amph-DOX) was purified by a C4 reverse-phase HPLC
column (Thermo Scientific, 250 x 4.6 mm, 5 µm). 200 µL samples were injected
and separation using a solvent gradient (Table 2.2.2.1) with methanol and
triethylammonium acetate (TEAA, 0.1 M pH = 7.4) buffer. The elution and
concentration of DSPE-PEG2000-DOX was monitored by measurement of the UV
absorbance at 260 nm and 485 nm. The chromatography spectra of product were
eluted at 13min and product was collected from 12 min to 14 min. After that
resulting component was sir dried and dissolve in DMSO again. 1H-NMR (Varian,
400 MHz) and Mass spectrum (Bruker Daltonics MALDI Ultraflex Extreme
TOF/TOF) were used to characterize DSPE-PEG2000-DOX (amph-DOX).
Table 2.2.2.1 HPLC gradient for purification of DSPE-PEG2000-DOX.45
Time

Methanol

0.1 M TEAA

0.00

50.0

50.0

10.00

100.0

0.0

15.00

100.0

0.0

15.01

0.0

100.0

20.00

0.0

100.0

Doxorubicin were loaded into DSPE-PEG2000 micelles by the single solvent
film casting method. Briefly, doxorubicin hydrochloride (2 mg, 3.5 mmol) preactivated with triethylamine (TEA, 7 mg ,7 mmol) at a 1:2 molar ratio in methanol
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for 1 h at RT, subsequently was mixed with 20 mg DSPE-PEG2000 in chloroform.
Solvent in the mixture was air dried at RT for overnight, resulting a thin film. The
dried film was then mixed with 1mL D.I water and stirring at 60 °C for 20 min. Free
un-entrapped doxorubicin existing in the supernatant were separated by
centrifugation (5500 rpm,15 min).
2.2.3 Dynamic light scattering (DLS).
The size of amphiphilic DOX micelles was analyzed by zetasizer (Nanosizer
ZS, Malvern Instrument) at 25 °C. 10 µM amphiphilic DOX was dissolved in PBS
and incubated in presence of or absence of BSA at 37 °C for 4 h. Micelles were
added to the microcuvette (ZEN0040, Malvern Instrument) and started the Zeta
sizer measurement to measure the products hydrodynamic diameter (DH). The
hydrodynamic diameter was determined using Stokes−Einstein equation: DH =
(kT/3πηD). In Stokes−Einstein equation, D is diffusion coefficient, referring via the
cumulant fitting from autocorrelation function; T is temperature, 25 °C; η is viscosity;
k is the Boltzmann constant.
2.2.4 Electrophoretic mobility shift assay (EMSA).
An agarose gel EMSA technique was used to characterize the binding
between albumin protein and amphiphilic DOX. 10 μM free DOX and amphiphilic
DOX dissolved in phosphate buffered saline (PBS, pH 7.4) were incubated with
mouse blood for 4 hours at 37 ˚C, resulting in 1 mL mixtures in total volume. 0.5
mL of the samples were used for fluorescent analysis and gel electrophoresis shift
assay and the other 0.5 mL were used for flow cytometry analysis. After
centrifugation, 20 µL samples were premixed with glycerin and loaded for
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electrophoresis and the all gels were run under 200 V for 30 min. Images were
recorded using a digital camera (Canon EOS) under UV illustration.
2.2.5 Fluorescence resonance energy transfer assay 1.
Fluorescence resonance energy transfer

1

assay was employed to

demonstrate the binding between albumin and amphiphilic DOX. 30 mg of BSA
dissolved in PBS was firstly labeled with 2.1 mg of Alexa 660 dissolved in DMSO
for 4 h at RT. After coupling, the product was purified using gel-filtration column
(MidiTrap G-25, Sigma-Aldrich) and analyzed by HPLC. 10 μM amphiphilic DOX
or free DOX were incubated with above Alexa 660 labelled bovine serum albumin(BSA-Alexa660) complex in PBS (pH 7.4) buffer for 4 h at 37 °C. After that,
samples were analyzed by spectrofluorometer (JASCO FP-6500). DOX or
amphiphilic DOX were excited at 470 nm and the fluorescence spectra were
monitored from 550 nm to 650 nm in wavelength.
2.2.6 Membrane insertion and cellular uptake studies.
The membrane insertion and cellular uptake of unmodified DOX and
amphiphilic DOX were quantified in B16F10 cells by flow cytometry (Applied
Biosystems). Cells with a density of 1 × 106 cells per well were seeded in a 96wells plate for overnight. For membrane insertion determination, the cell medium
was removed and replaced with 1.0 µM DOX and amphiphilic DOX in cold cell
culture medium for different time periods at 4 °C. For uptake quantification, the cell
medium was removed and replaced with 1.0 µM DOX or amphiphilic DOX in cell
culture medium for different time periods at 37 °C. After washing three times with
PBS, cells were harvested in fluorescence-activated cell sorting (FACS) buffer and
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analyzed by Attune acoustic focusing cytometer. Each assay was performed in
triplicate.
2.2.7 Mechanism of cellular entrance.
1 × 106 B16F10 cells were seeded in full cell culture medium in 96-wells
plate at 37°C. After overnight incubation, cells were incubated in the presence or
absence of 5 μg/mL filipin (FLP), 10 ug/mL ethyl-isopropyl amiloride (EIPA), or 0.1
M sucrose for 30 min. 1 μM amphiphilic DOX or DOX loaded micelles were added
to each well and incubated for another 4 h. After incubation, cells were
centrifugated and washed three time using PBS for flow cytometry analysis.
2.2.8 In vivo pharmacokinetics values.
To measure the pharmacokinetics in vivo, 100 µL B16F10 melanoma cells
(107 cells/mL) suspended in sterilized PBS were subcutaneously (s.c.) inoculated
in the flank region of 5-weeks C57BL/6 mice. When the tumor size reached ~500
mm3, mice were randomly divided into three groups (n = 8 mice per group). Free
doxorubicin (10 mg/kg), amphiphilic DOX (10 mg/kg equivalent doxorubicin) or
PBS were intravenously administrated at tail vein into the tumor bearing mice. 50
μL blood samples (n = 4 at each time point) were collected into the heparinized
tubes at 30 and 60 min, 2, 4, 6, 12 and 24 h after drug administration and then
centrifuged at 15,000 × g for 10 min to isolate the blood plasma. Sera were mixed
with two equal volumes of PBS and drug concentrations in sera were interpolated
from standard curve by measuring the fluorescence intensity at 585 nm in each
sample, normalized with sera from non-treated animals. The standard curve of
drug was established by mixed known concentration of DOX to homogenates of
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mixture of PBS and non-treated sera samples. Half-life (t1/2) was interpolated from
doxorubicin concentrations in the area vs. time curve and stimulated by one-phase
exponential decay method (Graphpad prism).
2.2.9 In vivo biodistribution study.
For tracking the in vivo distribution, a total number of twenty-four B16F10
melanoma tumor bearing C57BL/6 mice (tumor volume ~500 mm3) were randomly
separated into three groups. Mice injected intravenously with either free
doxorubicin (10 mg/kg), amphiphilic DOX (10 mg/kg equivalent doxorubicin) or the
same volume of PBS. In each treatment group, mice were euthanatized under
carbon dioxide inhalation at 2 or 24 h after drug administration (n = 4 at each time
point). The tumor, spleen, heart, brain, lung, kidney, and liver tissues were
collected. Tissue samples were liquid nitrogen frozen and stored at −80 ˚C until
drug extraction.
To extract drug from tissues, each sample were weighed and smashed by
tissue homogenizer (Biomasher II tube, Kimble) and sonicated with nine parts (v/w)
of PBS. 200 µL homogenate were combined with 50 µL Triton X-100 solution (10%,
v/v, BioVision, Inc.) and 750 µL HCl (0.75 N, Sigma-Aldrich) in dichloromethane
(DCM). The mixture was incubating at −20 ˚C for 12 h in the dark and vortexed at
room temperature after thawing. Samples containing drug were isolated by
centrifugation at 20,000 × g for 20 min (4 ˚C). Fluorescence intensity was
measured and corrected against extracts from tissue samples of non-treated
animals. A standard curve was interpolated by titration known concentration of
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doxorubicin to homogenates of mixture of PBS and non-treated tissue samples
prior to extraction.
2.2.10 Tumor model.
B16F10 (5.0 × 105 cells in 100 µL PBS) were subcutaneously inoculated
into the left flank of 5-6-weeks C57BL/6 mice. When the tumor volumes reached
30 mm3 (on day 5), mice were divided into three treatment groups (n = 8). The
tumor-bearing mice were intravenously injected with either 5 mg/kg doxorubicin
hydrochloride, amphiphilic DOX or PBS every 72 h (on days 5, 8, and 11) in total
three times. Tumor length(L) and width(W) were measured with calipers, and the
tumor volume was calculated using the following equation: Tumor volume (V) =
0.5 × L × W 2.
2.2.11 Hematoxylin and eosin (H&E) staining.
Heart samples were isolated and performed formaldehyde-fixed and
paraffin-embedded. Hematoxylin and eosin immunohistochemical (H&E) staining
was applied on the fixed heart samples. After staining, pathology was observing
the slides under a microscope, cell nuclei were colored purple-blue and positive
area were orange. Figures of each slide were selected randomly and analyzed
using Fiji ImageJ (Bethesda, Maryland) image analysis software.
2.2.12 Statistical analysis.
The mean values of two groups were performed using unpaired Student’s t
tests. The statistical difference between groups were determined using a one-way
analysis of variance 20 with Bonferroni post-test. All the values were expressed as
means ± standard error of mean. GraphPad Prism (San Diego, CA) software was
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used for all the statistical analyses. ***p < 0.001, **p < 0.01, *p < 0.05, NS, not
significant.
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2.3 Results and discussions.
2.3.1 Design of albumin-based self-delivery amphiphilic conjugates.

Figure 2.3.1.1 Target lymph node by albumin-based self-delivery vaccines.
(A) Schematic of the design of albumin-based self-delivery vaccines. (B) Sizeexclusion chromatography of CpGs, Cho-CpGs, C18-CpGs or Lipo-CpGs alone or
following incubation with FBS for 2h. (C) Fluorescent amphiphiles were injected
s.c. at the tail base, lymph nodes were isolated and imaged 24 hours post injection.
(D) SIINFEKL tetramer of C57BL/6 mice (n = 4-8/group) after immunization with
ovalbumin (10 μg) + CpG (1.24 nmol).25
Endogenous albumin protein based self-delivering system is a promising
approach in targeting tumor tissues in vivo.

120, 130

We recently proposed an

‘albumin-hitchhiking’ approach which efficiently delivered therapeutic agents to
lymph nodes (LNs).35 As we illustrated in Figure 2.3.1.1A25, subunit vaccines were
covalently conjugated to a lipophilic tail which optimized for albumin binding in
structure through a solubility-promoting polar polymer. Following subcutaneous
injection, this amphiphilic vaccine has a high affinity to endogenous albumin

40

protein, draining to the lymph node through lymphocytic fluid 35. Lipid-based
amphiphiles self-assembling into micelles were observed in aqueous buffer 135.
However, these micelles were supposed to be formed at a higher concentration of
monomer (above the critical micelle concentration, CMC) and were kinetically
unstable especially in the presence of proteins such as albumin 35, 76, 135. In addition
to protein absorption, these amphiphilic molecules with a lipid tail also exhibited
plasma membrane insertion property, as demonstrated by the rapid uptake and
intracellular delivery35, 136-137. Thus, in the presence cells and serum, there existed
a complicated three-way equilibriums: micelles were self-assembled from
amphiphiles, amphiphiles in the single chain state can also insert their diacyl tails
into cell membranes or bind to albumin protein. This three-way equilibrium was
delicately regulated by 1), the length of both lipid tails and PEG that a long diacyl
lipid (≥ 16 carbons) and a long polyethylene glycol (≥ 36 EG units) favors the
albumin binding in vivo35, 135, 138; 2) The in situ albumin concentration. In order to
translate this ‘albumin-hitchhiking’ approach to deliver anti-cancer drugs, we
modified doxorubicin with a structural optimized albumin-binding diacyl lipid linked
by a polyethylene glycol linker (Figure 2.3.1.1A)

25.

Instead of chemically

conjugating the anti-cancer drugs to an albumin ex vivo, we proposed to design a
novel amphiphilic drug which can bind rapidly to endogenous albumin. Albumin
binding dramatically increased the molecular drug’s size and transported the drug
to disease site via enhanced permeation and retention effect (EPR) 125 or receptor
mediated uptake. We hypothesized that the amphiphilic functionalization can alter
doxorubicin’s

physicochemical

properties,

which

in

turn

re-defined

its
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pharmacological characteristics, improved its therapeutic anti-tumor efficacy and
reduced DOX-associated side effects.

Figure 2.3.1.1 Synthesis and Nuclear Magnetic Resonance (NMR)
characterization of amphiphilic doxorubicin. 45 (A) Amphiphilic DOX was
synthesized by conjugating of doxorubicin hydrochloride (DOX) to DSPE-PEG2000NHS. (B) 1H-NMR spectra of amphiphilic DOX. The proton peaks of DOX (c, d,
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and e) and DSPE-PEG (a, b) were observed at 8.5~7.0 ppm and 0.9~3.6 ppm,
respectively.

The structure of amphiphilic doxorubicin can be divided into three distinct
segments (Figure 2.3.1.1A)

45:

a diacyl lipid tail as albumin-binding and

membrane-anchor domain, a central repeat block containing ethylene glycol

35

units and DOX conjugated to the end of EG. The synthetic route of DSPE-PEG2000DOX was simply coupling doxorubicin hydrochloride and 1,2-Distearoyl-snGlycero-3-phosphoethanolamine (DSPE) conjugated polyethylene glycol (PEG
2000) with active succinimidyl ester (DSPE-PEG2000-NHS) via amide linkage. The
final conjugates were analyzed and purified by reverse phase HPLC
chromatography. As shown in Figure 2.3.1.1B45, the Nuclear Magnetic
Resonance (NMR) of amphiphilic DOX was measured in DMSO-d6. The proton
peaks of DOX (c, d, and e) and DSPE-PEG (a, b) were observed at 8.5~7.0 ppm
and 0.9~3.6 ppm, respectively. The original integration of peak 4 was set broadly
which contains the water peak at 3.3 ppm.
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2.3.2 Amphiphilic doxorubicin avidly binds to circulating serum albumin.

Figure 2.3.2.1 Albumin-binding properties of doxorubicin hydrochloride
(DOX) and amphiphilic doxorubicin were assayed by fluorescence
resonance energy transfer 1.45 40 µM Alexa 660 labeled bovine serum albumin
(BSA-Alexa 660) were incubated with either DOX or amphiphilic DOX in PBS (pH
7.4) for four h at 37 °C. After incubation, samples were excited at 470 nm using
spectrofluorometer (JASCO FP-6500), and the emission were collected ranging
from 540 to 750 nm.
To demonstrate the albumin binding property of amphiphilic DOX, albuminbinding properties of doxorubicin hydrochloride (DOX) and amphiphilic DOX were
assayed by fluorescence resonance energy transfer 1 binding assay 139. Alexa 660
labeled bovine serum albumin (BSA-Alexa 660) were synthesized by coupling BSA
and Alexa 660 in the presence of TEA. Binding assays were prepared by adding
excess BSA-Alexa 660 (40 uM) in PBS buffer with 10 μM either DOX or amphiphilic
DOX at 37 °C. After 4 hours of incubation time, the mixtures were transferred in 1
cm path length quartz cuvettes and analyzed by spectrofluorometer (JASCO FP6500). Figure 2.3.2.145 displayed the emission spectra excited for these samples.
Emission spectra obtained from PBS buffer of pure 10 μM DOX (red line),
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amphiphilic DOX (green line) and 40 µM Bovine serum albumin (BSA)-Alexa 660
(black line) were also exhibited for comparison. The maximum excitation
wavelength of DOX at 470 nm was used for all samples. At this wavelength, DOX
or amphiphilic DOX excitation occurred with high efficiency, while direct BSA-Alexa
660 excitation was negligible. In the absence of BSA-Alexa 660, the solution of
amphiphilic DOX and DOX mainly showed the fluorescence emission from DOX
(565 nm) when excited at 470 nm. However, the increase in emission from BSAAlexa 660 (690 nm) with concomitant suppression of amphiphilic DOX (565 nm)
was observed in the presence of BSA-Alexa 660, clearly indicating FRET occurring
from amphiphilic DOX to BSA-Alexa 660.
To test whether amphiphilic DOX conjugates can bind to endogenous
serum albumin, free doxorubicin hydrochloride or its amphiphilic conjugates were
incubated with freshly isolated mouse blood. The quantification and interaction of
drug with serum albumin were analyzed by fluorescence spectroscopy (Figure
2.3.2.2B) 45 and gel shift electrophoresis (Figure 2.3.2.2C) 45. Parallelly, the whole
blood samples were analyzed by flow cytometry. Upon co-cultured with blood
containing cells and plasm proteins, 9.8% of free DOX was detected in the
erythrocytes, which was almost three times more than that of amphiphilic DOX
(Figure 2.3.2.2A) 45.

45

Figure 2.3.2.2 A majority of amphiphilic DOX, instead of free DOX can bind
to serum albumin in blood. 45 (A-C) Fresh isolated blood from mice were
incubated with DOX or amphiphilic DOX at a final concentration 0.5 μM for 4 h.
After separation, whole blood cells were analyzed by flow cytometry (A) and sera
were isolated to quantify the content of drug via fluorescence spectroscopy (B) and
binding status were visualized by gel shift assay (C). 45
This observation was consistent with previous publications and suggested
adriamycin interacts with blood cells 138, 140-142 By comparison, despite being in the
possession of lipid tail for membrane insertion, amphiphilic DOX had less
association with the cells in the blood (3.6%). Fluorescence spectroscopy
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measurements indicated that 92% of amphiphilic DOX and 18% of free DOX
remained in the blood serum (Figure 2.3.2.2B) 45. Further, gel electrophoresis
analysis (Figure 2.3.2.2C) 45 of drug incubated with blood showed a light-orange
fluorescent band from amphiphilic DOX co-migrated with albumin (Figure 2.3.2.2C,
lane 5) 45, suggesting that the majority of the amphiphilic DOX existing in serum
albumin/ amphiphilic DOX status. This band was distinct from albumin as pure
serum showing a green color under ultraviolet light (254 nm) which came from
protein autofluorescence. In contrast, two individual band in the opposite direction
of loading well were observed in free DOX incubated with blood. DOX possesses
a single positive charge and migrated as a single band toward the negative
electrode (Figure 2.3.2.2C, lane 4) 45, indicating a lack of interaction with negative
charged albumin protein in the gel. Size exclusion HPLC spectra (data not shown)
showed that amphiphilic DOX was eluted at 6.7 min indicating a large size
aggregation. While incubating with mouse blood, the aggregation was
disassembling and co-eluted with serum at 9 min. These results strongly
demonstrated that, unlike unmodified DOX, which extensively interacted with cells
in blood, amphiphilic DOX can bind to plasma albumin in blood vessel and warrant
further investigation of albumin-based self-delivery platform for drug delivery.
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2.3.4 Three-way equilibriums of amphiphilic doxorubicin.

Figure 2.3.4.1 The membrane insertion property of amphiphilic doxorubicin.
45 (A) DOX or amphiphilic DOX (1 µM) were co-cultured with B16F10 cells in 10%
FBS at 4 °C or 37 °C. Uptake was quantified by flow cytometry. (B) Cellular
distribution was analyzed by confocal microscope.
DSPE lipid was observed to spontaneously anchor and penetrate cells
driving by the hydrophobic effect indicating the importance of lipid-membrane
fusion as a forerunner to cell entrance.

To explore the membrane insertion

property of amphiphilic DOX, freshly trypsinized B16F10 cells were incubated with
DOX salt or amphiphilic DOX at 4 °C to maximally inhibit internalization and the
uptake were determined by flow cytometry. Amphiphilic DOX showed a rapid
internalization at 1h and peaked after 4 h incubation. The uptake of amphiphilic
DOX was more than four-fold than that of free DOX.

Confocal images also

indicated membrane insertion and rapid internalization of amphiphilic DOX via
endocytic recycling (Figure 2.3.4.1B)

45.

These results suggested amphophilic

modification enhanced cell entry partially due to the membrane insertion and it was
suspected that multiple routes were involved in the internalization process. The
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uptake of amphiphilic DOX in vitro (e.g., cell culture environment) was very
complicated in that: there exists a three-way equilibrium (Figure 2.3.4.2) 45 when
amphiphilic DOX was incubated with cells. Amphiphilic DOX can exist as micelle
states, albumin-binding state, and cell membrane insertion state. This has made
the mechanism study very difficult as in vitro (typically, 10% FBS, note that the
albumin concentration is approximatively ten times less than that in blood), all
these states can enhance the cellular uptake as compared to free DOX.

Figure 2.3.4.2 Self-assemble, membrane-insertion, and albumin-binding
properties of amphiphilic DOX. 45In aqueous solution, spherical micelles are
self-assembled from amphiphilic DOX with a DOX-PEG sunglow and a lipid core.
In the presence of albumin and cells, the micelle structure is disrupted by binding
to albumin (albumin hitchhiking) or inserting on plasma membrane (membrane
insertion). The structure of lipid-polymer (e.g., the length of lipid and PEG) and
albumin concentration govern the equilibrium partitioning between albumin binding
state or membrane insertion state. Current structure (DSPE-PEG2000) was
optimized for albumin-binding based on our previous finding. At high
concentrations of albumin (e.g., 640 μM in blood), the equilibrium strongly favors
albumin-binding. 45
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2.3.5 Analysis of uptake pathway under three-way equilibrium.
In the three-way equilibrium (Figure 2.3.4.2) 45 we proposed, amphiphilic
DOX can enter cell in three different formulas: self-assembling particle,
albumin/amphiphilic DOX complex or single-chain amphiphilic DOX. We firstly
compared the cell internalization of amphiphilic DOX with DOX loaded DSPEPEG2000 micelles. Doxorubicin were entrapped into DSPE-PEG2000 micelles by the
film casting method

143.

Briefly, doxorubicin hydrochloride (2 mg, 3.5 mmol) in

methanol was pre-treated with triethylamine (TEA, 7 mg, 7 mmol) at a 1:2 molar
ratio for one hour at RT, then mixed with 20 mg DSPE-PEG2000 in chloroform. The
DOX loaded DSPE-PEG2000 micelles were obtained under a stream of air form a
thin film and hydrated with D.I water. Cells were incubated with 1 uM DOX,
amphiphilic DOX or equal molar DOX loaded micelle for 4 h at 37 °C. Cellular
uptake was evaluated using mean fluorescence intensity quantified by flow
cytometry of treated cells. Consistent with previous study, increased uptake was
observed in amphiphilic DOX compared with cells treated with DOX (Figure
2.3.5.1A) 45. As we expected, amphiphilic DOX showed a superior cell entrance
ability comparing with DOX loaded micelles, indicating amphiphilic DOX uptake
through multiple channel which was not entirely the same with DSPE-PEG
encapsulated DOX nanoparticles.
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Figure 2.3.5.1 The amphiphilic DOX can exist in three statuses in vitro and
the uptake pathway were complicated. 45 (A) Cellular uptake of amphiphilic DOX
and DOX loaded DSPE-PEG2000 micelle in 10% FBS. (B and C) B16F10 cells were
pretreated with different inhibitors and then incubated with amphiphilic DOX or
DSPE-PEG2000 micelles. Cellular uptake was measured by flow cytometry.
Endocytosis or endocytosis-like internalization routine are the main
pathways of entrances for lipoplexes. To investigate the difference of uptake
pathway between amphiphilic DOX and DOX loaded DSPE-PEG2000 micelles in a
cell culture condition, cells were cultured with filipin, the caveolae transport inhibitor,
or sucrose, the clathrin-mediated inhibitor, or EIPA (inhibitor of macropinocytosis).
50-65% of internalization were inhibited by sucrose, filipin and EIPA suggesting
multiple mechanisms were involved in the uptake of amphiphilic DOX (Figure
2.3.5.1B) 45. In contrast, the uptake of DOX loaded DSPE-PEG2000 micelles were
primarily affected by the inhibitor of clathrin-mediated pathway (Figure 2.3.5.1C)
45.
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Figure 2.3.5.2 BSA competed with cells to bind amphiphilic DOX in a certain
time but was not a hinder of internalization. 45 (A and B) B16F10 cells uptake
of free DOX and amphiphilic DOX in different concentrations of FBS was examined
by flow cytometry. (C) Uptake of amphiphilic DOX in the presence of low (1 μM) or
high (1 mM) bovine serum albumin.
The stability of self-assembling amphiphilic dox micelles were characterized
by DLS, demonstrating deconstruction of particle in the in the presence of serum
albumin. To investigate the role of albumin in amphiphilic DOX internalization
process, we evaluated the uptake and intracellular distribution of amphiphilic DOX
in the presence and absence of albumin in a cell culture environment. In vitro, at
first two hours, uptake of amphiphilic DOX showed negatively correlated with FBS
content, reflecting the shift of equilibrium lay to the direction of cellular membrane
insertion at low albumin concentrations (Figure 2.3.5.2 A and B) 45. However, after
longer time incubation, partition between cellular uptake and albumin binding was
observed for amphiphilic DOX in the various of FBS content (the major protein in
FBS is albumin) in B16F10 cells. The results suggested that high concentrations
of albumin would 1) drive the equilibrium toward an albumin-binding state and 2)
the free albumin would compete with albumin-bound amphiphilic DOX for uptake,
reducing the amphiphilic DOX’s cellular uptake. Figure 2.3.5.2C45 showed the
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uptake results from low concentration (1 μM) or high concentration (1 mM) albumin
protein. As expected, the presence of extra albumin greatly reduced the uptake of
amphiphilic DOX (Figure 2.3.5.2C) 45, suggesting the amphiphilic DOX was indeed
bound to albumin. However, these data should not be simply interpreted as
albumin does not facilitate the tumor uptake. Rather, it demonstrated that the
uptakes were at similar levels no matter what state amphiphilic DOX was. In each
state, the uptake was significantly better when compared to unmodified DOX. It is
also worthy to mentioned that the concentration of albumin in blood is at least ten
times higher than that in a typical cell culture environment (10% FBS). At this
concentration, the majority of amphiphilic DOX binds to albumin protein (Figure
2.3.2.2)

45.

Taken together, the data we collected suggested amphiphilic DOX

reached tumor cells by binding and trafficking with albumin protein. In vitro, the
uptake of amphiphilic DOX in its micellar formulation appeared to be equally
efficient when compared with albumin-binding formulation, both of which were
significantly greater compared with free DOX.
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2.3.6 Albumin binding amphiphilic DOX extends half-life, alteration drug
distribution and improves the therapeutic anti-tumor efficacy.

Figure 2.3.6.1 In vivo plasma pharmacokinetic evaluation and biodistribution
of amphiphilic DOX in B16F10 tumor bearing C57BL/6 mice model. 45 (A)
Time-drug concentration profile in plasma of DOX and amphiphilic DOX. Plasma
doxorubicin concentrations resulting from a single injection free doxorubicin (10
mg/kg) or amphiphilic DOX (10 mg/kg equivalent doxorubicin) as a function of time
post injection. (B and C) Tissues (kidney, heart, tumor, liver, spleen) content of
drug 2 h (B) and 24 h (C) after a single injection of either DOX and amphiphilic
DOX (equivalent doxorubicin at 10 mg/kg). The values are the mean ± SEM (n =
4).
Albumin based self-delivery systems are known to enhance drug residence
time in circulating blood.144-146 To test whether the amphiphilic DOX can prolong
serum half-life via associated with albumin, mice were i.v. administrated with
unmodified DOX or amphiphilic DOX. At various duration following injection, sera
were isolated from drug treated mice blood samples for evaluating the profile of
time-drug concentration. In vivo, unmodified DOX exhibited a rapid clearance from
the plasma and its concentration was negligible (less than 1 mg/L) in 30 min post
injection (Figure 2.3.6.1A)

45.

In contrast, amphiphilic DOX with same dosage

exhibited higher serum concentration and extended retention time, with a half-life
(3.0 h) in blood increased approximately 60-fold compared with that of free
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doxorubicin (0.22 h). Besides reducing clearance, albumin-based self-delivery
amphiphilic DOX is also expected to accumulate in tumor via multiple principles:
1) due to the EPR effect, albumin/drug complex favorably accumulates in tumor
relative to normal tissues; 2) albumin protein has an extraordinarily universal
penetration capability via Fc receptor-mediated transcytosis in both normal and
malignant tissues.145, 147 iii) Under the pressure of malignant cellular metabolism,
tumor cells and tissues take up albumin protein as a source of amino acid and
nutrient.145,

147

Meanwhile, the recruit of albumin protein in health organs are

supposed to be relatively low due to the clathrin-mediated albumin recycling
pathway.148 Compared with unmodified drug, B16F10 tumor bearing mice treated
with amphiphilic DOX were exhibited 15-fold amount of drug extracted from tumor
tissue 24 h post injection (Figure 2.3.6.1C) 45. Moreover, amphiphilic DOX resulted
in a significantly lower heart accumulation of drug compared to unmodified DOX
(Figure 2.3.6.1B and C) 45, suggesting amphiphilic DOX might lead to a reduction
of the potential DOX- related temporary and permanent cardiotoxicity.
We next evaluated the antitumor activities of amphiphilic DOX by
therapeutically treating B16F10 melanoma tumor bearing C57BL/6 mice. At day 0,
amount of 5 × 105 B16F10 cells in PBS were subcutaneously inoculated into the
right flank of the mice. Mice received three injections of 5 mg/kg of unmodified
DOX, or amphiphilic DOX, or PBS on days 5, 8, and 11. As shown in Figure
2.3.6.2A45, administration of unmodified DOX showed a transient inhibition of
B16F10 tumor at the early stage of the treatment, while therapeutic effect quickly
regress when treatment termination on day 11. In contrast, mice treated with the
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same doses of amphiphilic DOX markedly delayed the tumor growth, suggesting
a progress of DOX- related chemotherapy (Figure 2.3.6.2A and C) 45. Treatment
with amphiphilic DOX also diminished doxorubicin-induced losses in total body
weight (Figure 2.3.6.2B) 45.
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Figure 2.3.6.2 In vivo anti-tumor activity of amphiphilic DOX in melanoma
bearing mice model. 45 (A and B) Tumor growth inhibition by amphiphilic DOX.
Mice were injected with doxorubicin hydrochloride, or amphiphilic DOX, or PBS.
All groups (n = 8) of mice received above treatments (5 mg/kg equivalent
doxorubicin, 10 μL/g of the body weight) on days 5, 8 and 11 by intravenous
injection in the lateral tail vein. Tumor volumes (A) and body weight (B) were
regularly measured during the experimental period. (C) Tumor photographs of
whole animals (day 15 after tumor inoculation) and after isolation. To evaluate
cardiotoxicity, C57BL/6 mice tumor free were treated with DOX or amphiphilic DOX
(10 mg/kg of body weight) at days 5, 8, and 11, and a maximum dose of 20 mg/kg
on day 16. Representative photomicrographs of heart sections of DOX and
amphiphilic DOX treated. (D) H&E staining of myocardium sections from tumorfree mice. Vacuole structures are indicated with black arrows.45
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In clinical, doxorubicin-induced cardiotoxicity can be highly possible and
acute. 149 To investigate the cardiomyopathy established by DOX, H&E staining of
cardiac muscle sections was analyzed of mice after administrations on days 5, 8
and 11. Histopathological analysis of heart section (on day 15) of amphiphilic DOX
treated mice showed no sign of defective heart muscle and negligible cardiotoxicity,
similar to those with no treatment control (Figure 2.3.6.2D). However, DOX treated
animals showed noticeable, albeit mild damage to cardiac tissue, characterized by
increased cytoplasmic vacuolization and distorted myocardial cell arrangement
(Figure 2.3.6.2D). In conclusion, there results demonstrated the albumin-based
self-delivery amphiphilic DOX can prolong drug circulating period, increase drug
delivery to tumor tissue via associated with endogenous albumin protein leading
to enhanced antitumor efficacy. Though the permanent DOX-related side-effect
and cardiotoxicity cannot be determined by our model, the reduced mouse cardiac
tissue accumulation and no cardiomyocyte pathology also guarantees a potential
security profile for myocardial tissue in the preclinical model.
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2.4 Conclusions.
In recent years, anti-cancer drugs delivered by nanoparticles can satisfy the
needs of lowering the dose and decreasing side effects, as well as achieve the aim
of combining multiple therapeutic agents.

150-152.

Currently, many systems are

under investigation for drug delivery and more specifically for cancer therapy.
Because the potential toxicity and interaction with tissue and cells greatly depends
on the actual synthetic of the nanoparticle composition, nature biological
components like albumin, gelatin and phospholipids for liposomes rather than nondegradable materials like inorganic and solid metal containing nanoparticles are
preferred150. Instead of chemically conjugate the anti-cancer drugs to an albumin
ex vivo, we designed a novel amphiphilic anti-cancer drug which can bind rapidly
to endogenous albumin as a drug carrier to target tumor residues at the local sites.
In this chapter, we conjugated the self-delivering amphiphilic DOX and
demonstrated that amphiphilic DOX can bind to endogenous albumin after
systemic injection as well as ex vivo ligand binding study. Due to the selfassembling and membrane insertion property of amphiphilic substance, the threeway equilibrium with their biological surroundings are discussed respectively. In
the presence of albumin and cells, the micellar structure is disrupted by binding to
albumin (albumin hitchhiking) or inserting on plasma membrane (membrane
insertion). However, albumin does not facilitate the tumor uptake in vitro. But in
vivo tumor model results suggested that amphiphilic DOX increase anti-tumor
efficacy via prolonging in body half-life of parental doxorubicin and enhancing
tumor specific accumulation. Altogether, the novel molecular and albumin-based
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self-delivery conjugate also features several favorable advantages as a cancer
therapeutic option: exogenous carrier-free and fully synthetic and molecularly
defined structure which has advantages in manufacturability, security and in
principle, could be readily translated to the clinic for cancer chemotherapy.
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Chapter 3. Amphiphilic doxorubicin specifically targets cell mitochondria.
3.1 Introduction.
3.1.1 Targeting mitochondria for cancer therapy.
Mitochondria are special subcellular components that play a key role in
mediation of essential cellular metabolism including lipid metabolism, adenosine
triphosphate (ATP) production and apoptosis activation 153-154. Furthermore, the
mitochondria have been assigned to produce copious quantity of reactive oxygen
species (ROS) leading to DNA deconstruction and genetic flexibility

155-156.

Growing evidences suggest mitochondrial biochemistry energy, signaling and
biosynthesis are indispensable for tumorigenesis and progression 154. Thus,
mitochondria have been an emerging and attractive target for anticancer agent. To
explore the approach to targeting mitochondria of cancer cells, two levels of
specific accumulation are required: drug accumulation in the tumor site after
systemic administration, and then accumulation in the mitochondria when uptake
into tumor cells

157.

Attempt to achieve this multi-level targeting has included the

use of nanocarriers by which a tumor-specific ligand and a mitochondria ligand are
both conjugated. Thus, in cancer chemotherapy, a successful mitochondriotropic
delivery requires multi-levels of targeting: it must achieve sufficient circulating time
in blood for drug exposure, and must achieve tumor tissue- and tumor cell-specific
accumulation followed by mitochondria-specific accumulation.35, 158-164
There are multiple functionally different molecules that can interfere with
mitochondrial function currently being tested or in clinical trial. 165 For example, due
to the mitochondria membrane potential, delocalized lipophilic cations with positive

61

charge (DLCs) are efficiently accumulating within mitochondria driven by electrical
force.

166-172

However, the intrinsic toxicities associated with DLCs have limited

their applications in clinical development.173-174 Other approaches to target
mitochondria via synthetic amino-acid-based transporters or mitochondria derived
sequence (MTS)160,

175-177

are reported to exhibit specific mitochondrial

accumulation1, 178-179. Due to the considerable molecular size, poor water solubility
and lack of stability159,

170,

small molecular compounds such as delocalized

lipophilic components or mitochondria specific peptides fail to maintain drug
retention above target level and, in some cases, non-specific accumulation in brain,
heart, liver, and muscle.166 Mitochondria-target ligand decorated drug carriers are
demonstrated to offer many advantages compared with traditional small molecular
drugs alone.

144, 146-147, 163

Unfortunately, current nanocarriers are difficult to meet

all the criteria for multi-level drug targeting and increase the risk of immune
disorder resulting from complex formulation. Possible stability and toxicological
issues including immunogenicity also greatly restrict the nanocarrier’s clinical
application in the current stage.
3.1.2 Multi-drug resistance (MDR) in cancer chemotherapy.

Chemotherapy is a powerful intervention that can prevent tumor regression
and recurrence and, in some cases, completely cure cancer. This therapeutic
method is often used as a single-agent therapy or combined with other cancer
treatments. While chemotherapy might initially be effective, it is very common for
patients to develop resistance to such agents. In fact, drug resistance has emerged
as a major limitation which impedes chemotherapeutic agents against the
therapeutic outcomes, causing tumor recurrence and treatment failure

133, 152, 180.

62

In the past four decades, various mechanisms have been demonstrated
from drug sensitive cancers cells evolving to resistant cells. Some of these theories,
such as impairment of delivering anticancer drugs to tumor cells, and genetic and
epigenetic alterations of cancer cells that hinder the drug sensitivity 150-151. In order
to solve such problems, combining multiple anticancer therapeutic agents with
different transportation and lethal mechanisms or various cellular targets promises
the remedial effective and high cure rates. Unfortunately, cells genetically
expressing evolutional exchanges in functions confer simultaneous resistance to
many different structurally and functionally distinct drugs. This phenomenon,
known as multidrug resistance (MDR), is shown after generating drug resistance
experimental model in vitro. When treated with a single drug, cells would finally
express cross-resistance to other unrelated drugs. Resistance to natural
hydrophobic components, sometimes known as classical MDR, generally results
from over expression of adenosine triphosphate (ATP)-dependent efflux pumps
181-183.

Figure 3.2.1.1. Structures and anticancer drugs as substrates of Pglycoprotein (P-gp) transporter.43-45
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P-glycoprotein (P-gp) confers resistance against a wide variety hydrophobic
natural compounds that are either neutral or positively charged drugs including
paclitaxel184, vinblastine185 and doxorubicin

186.

As the firstly detected cellular

surface phosphoglycoprotein involving in MRD, P-gp is composed of 12
transmembrane α-helices (in two membrane-spanning domains) and two ATPbinding sites (Figure 3.2.1.1)187.

Stimulating by the binding of substrates, a

conformational change happens that the substrates are released either the outer
leaflet of the membrane (from which it can diffuse into the medium) or the
extracellular space186. And the second ATP site is supposed to recover so that it
can continuing binding and hydrolysis activity. 188
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3.2 Method.
3.2.1 Materials, cells and animals.
Doxorubicin hydrochloride salt was obtained from LC laboratories (Woburn,
MA).

1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine

(DSPE)

conjugated

polyethylene glycol (PEG 2000) with active succinimidyl ester (DSPE-PEG-NHS)
was purchased from Biochempeg scientific Inc (Watertown, MA). Cholesterol
polyethylene glycol (PEG 2000) NHS and DSPE-PEG2000-NHNH2 were ordered
from Nanocs Inc (New York, NY). Triethylamine (TEA), N-hydroxylsuccinimide
(NHS), bovine serum albumin (BSA), filipin (FLP), ethyl-isopropyl amiloride (EIPA)
and sucrose were purchased from Sigma-Aldrich (St Louis, MO). Alexa Fluor 660
NHS Ester (Succinimidyl Ester), NHS-Fluorescein (5/6-carboxyfluorescein
succinimidyl ester), alamarBlue reagent, MitoTracker green, Mitochondria-RFP
and MITO-ID were obtained from Thermo Fisher Scientific (Waltham, MA). Cells
were cultured in complete medium (RPMI1640, 10% fetal bovine serum (Greiner
Bio-one), 100 U/mL penicillin G sodium and 100 μg/mL streptomycin (Pen/Strep).
Mouse skin melanoma (B16F10) cell line, mouse mammary carcinoma (4T1) cell
line and EG7 cell line were ordered from ATCC. Human ovarian carcinoma
(OVCAR-8) cell line and its adriamycin resistant derivative (NCI/ADR-RES) cell
lines were obtained from National Institutes of Health.
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3.2.2 Design and conjugation of amphiphilic doxorubicin.

Figure 3.2.3.1 Molecular structure of amphiphilic doxorubicin (amph- DOX).58
The molecularly defined drug conjugate can be divided into three distinct
segments (Figure 3.2.3.1): a diacyl lipid tail as albumin-binding and membraneanchor domain, a central repeat block containing ethylene glycol (EG) units and
DOX conjugated to the end of EG. Briefly, doxorubicin hydrochloride (DOX, 5 mg,
8.6 mmol) and DSPE-PEG2000-NHS (38 mg, 5.7 mmol) were dissolved in dimethyl
sulfoxide (DMSO) and activated with triethylamine (TEA) at room temperature for
24 hours (Figure 2.3.1.1A)

58.

After the reaction, the solution was dried, re-

dissolved in PBS and analyzed by reverse phase HPLC. Amphiphilic DOX was
purified by a C4 reverse-phase HPLC column (Thermo Scientific, 250 x 4.6 mm, 5
µm). 200 µL samples were injected and separation using a solvent gradient (Table
2.2.2.1) 58 with methanol and triethylammonium acetate (TEAA, 0.1 M pH = 7.4)
buffer. The elution and concentration of DSPE-PEG2000-DOX was monitored by
measurement of the UV absorbance at 260 nm and 485 nm. The chromatography
spectra of amphiphilic DOX was eluted at 13 min and product was collected from
12 min to 14 min. After that resulting component was dried and re-dissolved in
DMSO. 1H-NMR (Varian, 400 MHz) and Mass spectrum (Bruker Daltonics MALDI

66

Ultraflex Extreme TOF/TOF) were used to characterize DSPE-PEG2000-DOX
(amphiphilic DOX).
3.2.3 Synthesis of pH sensitive amphiphilic doxorubicin.
Doxorubicin hydrochloride (DOX, 5 mg, 8.6 mmol) and DSPE-PEG2000NHNH2 (38

mg, molar ratio of DSPE-PEG2000-NHNH2: DOX = 1.5: 1) were

dissolved in dimethyl sulfoxide (DMSO) and activated with triethylamine (TEA) at
room temperature for 24 hours (Figure 3.3.4.2A) 58. After the reaction, the solution
was dried, re-dissolved in PBS and analyzed by reverse phase HPLC. pH sensitive
amphiphilic doxorubicin (DSPE-PEG2000-NHNH-DOX) was purified by a C4
reverse-phase HPLC column (Thermo Scientific, 250 x 4.6 mm, 5 µm). 200 µL
samples were injected and separation using a solvent gradient (Table 2.2.2.1) 58
with methanol and triethylammonium acetate (TEAA, 0.1 M pH = 7.4) buffer. The
elution and concentration of DSPE-PEG2000-NHNH-DOX was monitored by
measurement of the UV absorbance at 260 nm and 485 nm.
3.2.4 Preparation of doxorubicin loaded DSPE-PEG2000 micelles.
Doxorubicin were loaded into DSPE-PEG2000 micelles by the single solvent
film casting method. Briefly, doxorubicin hydrochloride (2 mg, 3.5 mmol) was pretreated with triethylamine (TEA, 7 mg ,7 mmol) at a 1:2 molar ratio in methanol for
1 h at RT, subsequently mixed with 20 mg DSPE-PEG2000 in chloroform. Solvent
in mixture was air dried at room temperature for overnight, resulting a thin film. The
dried film was then mixed with 1 mL D.I water and stirring at 60 °C for 20 min. Free
un-entrapped doxorubicin existing in the supernatant were separated by
centrifugation (5500 rpm,15 min).
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3.2.5 In vitro cytotoxicity.
The in vitro anti-tumor activities of the unmodified DOX and the amphiphilic
DOX against B16F10, 4T1, EG7, OVCAR-8 and NCI/ADR-RES cells were
assigned using AlamarBlue assay. B16F10, EG7 and 4T1 cells at the density of 5
× 104 cells per well and OVCAR-8 and NCI/ADR-RES cells at the density of 1 ×
105 cells per well were seeded in 96-wells plates for overnight at 37 °C. Cells were
replaced with cell culture medium with DOX or amphiphilic DOX at serial
doxorubicin concentrations ranging from 0.05 to 10 µM for 24 or 48 h, subsequently
with the addition of 10% (v/v) AlamarBlue reagent for another 1 h. Cells treated
with DMSO in complete medium were used as the no treatment controls. Finally,
the UV/vis absorbance of the whole cell residues was measured at 570 nm with
600 nm as a reference by a microplate reader (Thermo Scientific). The cell visibility
was calculated as the value of absorbance from treated cells normalized to none
treated cells. Dose-response curve was interpolated using Prism Graphpad
software (San Diego, CA) to determine the half maximal inhibitory concentration
(IC50). All the experiments were carried out in triplicate.
3.2.6 Cellular uptake studies.
The cellular uptake of unmodified DOX and amphiphilic DOX were
quantified in B16F10 cells by flow cytometry (Applied Biosystems). Cells with a
density of 1 × 106 cells per well were seeded to 96-wells plate for overnight. The
cell medium was removed and replaced with 1.0 µM DOX and amphiphilic DOX in
cell culture medium for different time periods at 37 °C. Following washed three
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times with PBS, cells were harvested in FACS and analyzed by Attune acoustic
focusing cytometer. Each assay was performed in triplicate.
3.2.7 Subcellular tracking study.
To track the intracellular location after internalization of unmodified DOX and
amphiphilic DOX, B16F10, NCI/ADR-RES as well as 4T1 cells at the density of 1
× 104 cells per well were seeded on a coverslip in 6-wells plates at 37 ˚C for 24 h
to achieve adhesion. To visualize mitochondria by MitoTracker Green FM, cells
were treated with 1 μM unmodified DOX or amphiphilic DOX at 37 ˚C for 4 h. After
treatment, the cells were washed three times with PBS, following incubating 500
nM with MitoTracker Green FM (Invitrogen) for 15 min and 200 nM DAPI
(Invitrogen) for another 15min. For CellLight Mitochondria-RFP BacMam 2.0
(Invitrogen) labeling mitochondria, cells were transfected with 10 µL CellLight
reagent in whole cell culture medium at 37 ˚C for 24 h. Then cells treated with 1
μM unmodified DOX or amphiphilic DOX were fixed with 3% paraformaldehyde
(PFA) and cocultured with 200 nM DAPI (Invitrogen) for 10 min. Slides samples
were washed with fresh PBS before imaging. Confocal microscopy images were
obtained by Zeiss microscope system (LSM 780) with a 63 × oil-immersion
objective. Parameters upon exciting/emission wavelength were set as below
(Table 3.2.7.1)

58:

doxorubicin (excitation 488 nm, emission 560 nm bandpass

filter), MitoTracker Green (excitation 488 nm, emission 515 nm bandpass filter),
CellLight Mitochondria-RFP (excitation 561 nm, emission 585 nm bandpass filter).
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Table 3.2.7.1 Confocal microscopy setting for mitochondria tracking. 58
Excitation

Emission bandpass

wavelength

filter

Doxorubicin

488nm

560nm

Amphiphilic DOX

488nm

560nm

MitoTracker Green

488nm

515nm

561nm

585nm

Reagents

CellLight MitochondriaRFP

3.2.8 In vitro colocalization analysis.
The level of colocalization was quantified by ImageJ (NIH, Bethesda,
Maryland) with Coloc2 plugin

189.

The level of colocalization between unmodified

DOX or amphiphilic DOX was evaluated on the account of the red to green signal
intensities and that with cell nuclei were based on red to blue signal intensities.
Pearson’s 190 and Manders’ (M1/M2) coefficients were calculated from an specified
cellular area of the whole view in each of the three independent experiments (total
12 fields).
3.2.9 Mitochondria and nuclei isolation.
1 × 108 per well of the B16F10 Cells were seeded in 15 mL of cell culture
medium in 100-mm diameter tissue culture dishes and allowed to grow overnight.
10 µM unmodified DOX and amphiphilic DOX were added to cells and incubated
for different time periods. Following manufacturer’s instructions. Intracellular
compartments from drug treated or untreated cells were isolated using a
mitochondria isolation kit (Thermo Fisher Scientific, Waltham, MA) and a nuclei
isolation kit (Sigma- Aldrich, St. Louis, Missouri), respectively. The percent of
unmodified DOX and amphiphilic DOX existing in each component were quantified
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by measuring fluorescence intensity from doxorubicin after solvent extraction
normalized with 10 µM standard samples. All the experiments were carried out in
triplicate.
3.2.10 Measurement of reactive oxygen species (ROS) generation.
B16F10 cells (1 × 106 cells/well) were pre-cultured in 24-wells plates for
overnight. Cells were then incubated with unmodified DOX and amphiphilic DOX
at a final concentration of either 1.0, 5.0 or 10.0 µM for four hours. After treatment,
cells

were

resuspended

in

PBS

and

incubated

with

10

µM

2',7'-

dichlorodihydrofluorescein diacetate (H2DCFDA), a ROS indicator, for 30 min at
37 °C. Finally, the cells were washed and analyzed by flow cytometry (Applied
Biosystems). No treatment group was used as a negative control for the
quantifications of mitochondrial ROS production.
For visualizing intracellular ROS generation, 1 × 104 cells were seeded on
square coverslips in 6-wells plates and treated with 10.0 µM unmodified DOX and
amphiphilic DOX for 4 h. After drug treatment, cells were resuspended in PBS and
incubated with 10 µM 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA), a
ROS indicator, for 30 min at 37°C. Finally, cells were stained with 500 nM
MitoTracker Green (Invitrogen) for 15 min and 200 nM DAPI (Invitrogen) with
another 15min. Imagines were captured by Zeiss microscope system (LSM 780)
with a 63 × oil-immersion objective.
3.2.11 Tumor model and confocal microscopy images of tumor tissue.
B16F10 (5.0 × 105 cells in 100 µL PBS) were subcutaneously inoculated
into the left flank of 5-6-weeks C57BL/6 mice. When the tumor volumes reached
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30 mm3 (on day 5), mice were divided into three treatment groups (n = 8). The
tumor-bearing mice were intravenously injected with either 5 mg/kg doxorubicin
hydrochloride, amphiphilic DOX or PBS every 72 h (on days 5, 8, and 11) in total
three times. Tumor samples were isolated on the last day of experiment and fixed
for 48h in formaldehyde fixation buffer. Each tissue was merged in optimal cutting
temperature compound, freeze at -80 ˚C in the dark and slice into 10 µm-thickness
tissue sections using a cryostat (Leica CM3050 S). The fixed tissue slides were
incubated with 100 µL MITO-ID Red (Enzo life sciences) reagent for 30 min and
200 nM DAPI for additional 15 min.
3.2.12 Statistical analysis.
Statistical analysis the mean values of two groups were performed using
unpaired Student’s t tests. The statistical difference between groups were
determined using a one-way analysis of variance (ANOVA) with Bonferroni posttest. All the values were expressed as means ± standard error of mean. GraphPad
Prism (San Diego, CA) software was used for all the statistical analyses. ***p <
0.001, **p < 0.01, *p < 0.05. NS, not significant.
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3.3 Results and discussions.
3.3.1 Amphiphilic modification increases DOX-induced antitumor effect in
multiple murine cell lines.

Figure 3.3.1.1 Amphiphilic DOX induced cytotoxicity in murine cell lines. 58
(A-C) In vitro cell viability of B16F10 (A), 4T1 (B), or EG7 (C) cells against
unmodified DOX and amphiphilic DOX for 24 h after exposure.
To compare the impact of amphiphilic modification on the DOX induced
antiproliferation efficacy, the cytotoxicity of several murine cancer cells, including
murine melanoma B16F10, murine mammary carcinoma 4T1 and the murine
thymoma EG-7 cell lines were evaluated. Data interpolation and the half maximal
inhibitory concentration (IC50) were calculated by Prism GraphPad (Table 3.3.1.1)
58.

Exposure of cells to amphiphilic DOX caused a dose-dependent viability, with

an IC50 value of 0.2299 μM in B16F10 cells, versus 0.6152 μM in cells cultured
with unmodified DOX (Figure 3.3.1.1A) 58. Similarly, treatment with amphiphilic
DOX reduced the IC50 values in 4T1 cells (0.05458 μM versus 0.1500 μM with free
DOX) and the EG7 cells (0.08746 μM versus 0.2805 μM with unmodified DOX)
(Figure 3.3.1.1B, C)

58.

As the negative controls, DSPE-PEG2000-NHS or its

hydrolyzed derivative exhibited negligible toxicity, suggesting amphiphilic DOX
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induce its cytotoxic effects in a DOX-dependent manner instead of amphiphilic
polymer.
Table 3.3.1.1 Amphiphilic modification increases DOX-induced antitumor
effect in multiple murine cell lines. 58

3.3.2 Amphiphilic modification overcomes drug resistance in breast
adenocarcinoma cells.

Figure 3.3.2.1 Amphiphilic DOX overcame drug resistance in breast
adenocarcinoma cells. 58 (A and B) In vitro DOX sensitive OVCAR-8 (A) and drug
resistance NCI/ADR-RES cells against unmodified DOX and amphiphilic DOX for
48 h exposure.
Chemotherapeutic agents such as anthracyclines have been shown to
induce cell apoptosis by a wide variety of mechanisms and have been a major
treatment modality for cancer, especially metastatic cancers. However, intrinsic or
evolutionary drug resistance greatly limited the development of anthracyclines (e.g.
DOX) in the clinical management of cancers. Overexpress of the drug pump
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receptors such as P-glycoprotein (P-gp) receptors on the cell membrane is the
major drug efflux pumps which is often associated with drug resistance.
Encouraged by the favorable tumor antiproliferation property of amphiphilic DOX,
we next evaluated their tumor killing efficiency in human cancer, including P-gp
overexpressed drug resistance cell line. Exposure with amphiphilic DOX reduced
the IC50 values (Table 3.3.2.1) 58 in both DOX sensitive OVCAR-8 cells (0.1094
μM versus 1.12 μM with unmodified DOX) (Figure 3.3.2.1A)

58

and the

anthracyclines resistant NCI/ADR-RES cells (0.4725 μM versus 0.7565 μM with
unmodified DOX) (Figure 3.3.2.1B)

58.

These results gave evidence that

amphiphilic DOX was considerably more potent than free DOX in both drug
sensitive and drug-resistant cell lines.
Table 3.3.2.1 Amphiphilic DOX overcame drug resistance in breast
adenocarcinoma cells. 58

3.3.3 Amphiphilic DOX accumulates in mitochondrial area in vitro.
To track the localization of amphiphilic DOX related to its parental
compound after cell uptake, B16F10 melanoma tumor cells were incubated with
DOX or amphiphilic DOX in the whole cell culture medium containing 10% FBS.
The internalization was analyzed by confocal laser scanning microscopy (CLSM).
As previously reported, unmodified DOX exhibited strong affinity to cell nuclei
showing the colocalization between red (DOX) and blue (nuclei) 191 (Figure 3.3.3.1)
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58.

In contrast, amphiphilic DOX fluorescence exists as the light red dots and was

mainly confined around the nuclear (Figure 3.3.3.1) 58. Through colocalization with
a mitochondria-specific dye (green, MitoTracker Green FM), it was demonstrated
that amphiphilic DOX was aggregating in mitochondrial area. (Figure 3.3.3.1,
upper two panels) 58. As in our previous observation, amphiphilic oligonucleotides
were mainly delivered within the endo/lysosomal compartment, the mitochondriaselective accumulation of amphiphilic DOX was unexpected.

Figure 3.3.3.1 Amphiphilic DOX accumulated in B16F10 cellular
mitochondrial area in vitro. 58 Subcellular tracking of unmodified DOX and
amphiphilic DOX at the incubating concentration of 1 µM in B16F10 cells. Cells
treated with either free DOX (red, from DOX intrinsic fluorescence) or amphiphilic
DOX were incubated with Mito-Tracker Green (green, upper two panels) or
Mitochondria-RFP (green, lower two panels). Cell nuclei were tracking with DAPI
(blue). Noting that some cells were not transfected in the Mitochondria-RFP treated
group. Scale bar = 10 µm.
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Table 3.3.3.1. Pearson's Correlation Coefficients and Manders’ coefficients.
58

To verify the mitochondria-specific accumulation, another transfectionbased red fluorescent protein (RFP) was used to label the mitochondrial area
(Figure 3.3.3.1, lower two panels). This reagent uses BackMam 2.0 technology
and is effective on a wide range of mammalian cell lines. The transfection process
was conducted according to manufacturer’s instruction by adding CellLight reagent
to cells for overnight. The cells were subsequently imaged. The transfection can
be seen by the RFP fluorescence under confocal microscope. We also noticed that
in our hands, not 100% of the cells were transfected (Figure 3.3.3.1, lower panel),
which is typical for a lot of transfection reagents. This partial transfection is also a
circumstantial evidence which rules out the possibility of fluorescence artifact of
the images. Colocalization coefficients assigned by Coloc 2 algorithm revealed
significant spatial overlapped between amphiphilic DOX with both mitochondria
dyes in B16F10 cells (Ps and Manders’ coefficients were shown in Table 3.3.3.1).
For unmodified DOX, low coefficient values were obtained indicating the weak
associations of the drug and the mitochondrial matrix (Table 3.3.3.1).

77

Figure 3.3.3.2 Amphiphilic DOX selectively accumulated in both B16F10 and
4T1 cellular mitochondria. 58 (A-C) Pharmacokinetic quantification of relative
drug tracking total cells (A), mitochondria (B) and (C) nuclei of DOX or amphiphilic
DOX treated B16F10 cells. B16F10 cells at the density of 1 x 108 per well were
incubated with 10 μM DOX or amphiphilic DOX for 1, 4, 12 or 24 h. Mitochondria
and nuclei compartments were isolated by commercial isolating kits. The
fluorescent intensity of each drugs was quantified by fluorescence
spectrophotometer after extraction. (D) CLSM images of amphiphilic DOX
(concentration of 1 μM) treated 4T1 cells showing the cellular uptake and
intracellular distribution of free doxorubicin or amphiphilic DOX at four hours.
Mitochondria tracking of 4T1 cells was employed MitoTracker Green reagent.
Scale bar = 10 µm.
Because DOX has intricate features intercalating to DNA, the drug
concentration in subcellular compartments could directly reflect the different
destination upon free DOX and amphiphilic DOX. To verify the observations on
uptake and distribution, the mitochondria and the nuclei the drug treated B16F10
cells were extracted and drug concentration were quantified by fluorescence
spectrophotometer. Similar to flow cytometry results (Figure 2.3.5.1A)

58,

cells

treated with free DOX reached approximately 50% (30% to 70%) of the uptake
from amphiphilic DOX-treated cells at different time points (Figure 3.3.3.2A) 58.
Consistent with CLSM colocalization analysis (Figure 3.3.3.1) 58, unmodified DOX
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had a high affinity to nuclei, accounting for 72% of the fluorescence localized within
the cells in 24 h (Figure 3.3.3.2 B and C)58. By comparison, approximately 45%
of the amphiphilic DOX was tracked in isolated mitochondria after 24h incubation
(Figure 3.3.3.2B and C)

58.

Although compared with free DOX, a fraction of

amphiphilic DOX might be lost during organelle isolation, other portion of them
were still under lipid sorting process or residue in cytosol. To investigate whether
the mitochondria accumulation of amphiphilic DOX was limited to B16F10 cell, we
tracked the drug location on mouse breast tumor 4T1 cells. Uniform mitochondrial
accumulation observed in 4T1 cells (Figure 3.3.3.2D) 58 clearly demonstrated the
selective mitochondria accumulation in murine tumor cells after treatment with
amphiphilic DOX.

Figure 3.3.3.3. Confocal microscopy imagines colocalization of amphiphilic
DOX with mitochondria or lysosomes. 58 (A and B) B16F10 cells were treated
with 1µM amphiphilic DOX and tracked mitochondria by MitoTracker Green (A) or
lysosome LysoTracker Green (B). Cell nuclei were stained with DAPI (blue). Scale
bar = 5 µm.
In addition, amphiphilic DOX employs multiple uptake mechanisms in
typical cell culture conditions which has been discussed in Chapter 2.3.5. Engulfing
molecules through endocytosis mechanisms are the main pathway for. Fusion of
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the lipid-based amphiphiles with the endosomal membrane is generally accepted
as a possible lipid sorting process to release lipoplex into the cytoplasm. To
investigate the role of lysosome/endosome in lipid sorting process as well as
intracellular distribution of lipid conjugated DOX related, colocalization between
amphiphilic DOX with either mitochondria or lysosomes were observed using
confocal laser scanning microscopy (CLSM). Amphiphilic DOX was synthesized
through DOX covalently conjugated with DSPE-PEG2000 which was not able to
release under intracellular environment. It was hypothesized that after lipid sorting
process, amphiphilic DOX was released and exposed in cytosol. Thus, we
colocalized amphiphilic DOX with subcellular organelles mitochondria (Figure
3.3.3.3.A, green)

58

and lysosome (Figure 3.3.3.3.B, green)

58.

Colocalization

coefficients assigned by Coloc 2 algorithm revealed significant spatial overlap
between amphiphilic DOX with both mitochondria dyes in B16F10 cells (Pearson
coefficient, 0.57; Manders coefficient, 0.874/0.992), whereas colocalization of the
amphiphilic DOX with lysosome (Pearson coefficient, 0.09; Manders coefficient,
0.415/0.241) showed little correlation.
3.3.4 Discussion of potential mitochondrial targeting mechanism.
Lipids spread all over the whole cell, trafficking from the cell surface to/
within the various organelle membrane where lipid metabolism happens. The
increasing evidence demonstrated that internalized lipid-based amphiphiles were
distributed to varies subcellular organelles in a lipid-specific manner.

192-193.

Structure of lipid-based amphiphiles is generally believed to govern the
intracellular sorting pathways and thus determines the distribution and destination
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of these components. However, few researches focused on the mitochondrial
targeting property of lipid-based amphiphiles. Since the same negative charge of
amphiphilic DOX (Figure 2.3.2.2)

58

with mitochondrial transmembrane

potentials194, it is unlikely amphiphilic DOX concentrating in mitochondria is driven
by electrostatic force. As clarified in chapter 2 (Figure 2.3.4.2) 58, we assumed that
amphiphilic DOX exists three status when incubating with cell and could possess
multiple uptake mechanism.

Figure 3.3.4.1 In vitro antitumor activity and subcellular location of DOX
capsulated DSPE-PEG2000 micelles. 58 (A-C) Cells internalization of DOX loaded
DSPE-PEG2000 micelles was examined by flow cytometry (A and B) and subcellular
location at 4h were analyzed by confocal microscope (C). B16F10 cells (5 × 105
cells per well) were seeded to 96-well plate at 37 °C for overnight. Cells were
incubated with DOX loaded DSPE-PEG2000 micelles (DOX concentration of 1.0 µM)
at for different time periods before flow cytometry analysis. (C) B16F10 cells at the
density of 1× 105 cells per well were seeded to 6-well plate for overnight. Cells
were treated with DOX loaded DSPE-PEG2000 micelles and MitoTracker Green for
mitochondria tracking, whereas cell nuclei were stained with DAPI (blue). Scale
bar = 10 µm.
To explore the potential explanation of mitochondria target, we compared
and discussed the three conditions individually. Polymeric micelles are reported to
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show a rapid internalization in most of tumor cells and disassemble and release
their content into cell cytosol once internalized. We firstly analyzed the intracellular
accumulation of amphiphilic DOX and DOX loaded DSPE-PEG2000 micelles. . DOX
loaded DSPE-PEG2000 micelles was synthesized by the film casting method. Briefly,
doxorubicin hydrochloride (2 mg, 3.5 mmol) in methanol was pre-treated with
triethylamine (TEA, 7 mg, 7 mmol) at a 1:2 molar ratio for one hour at RT, then
mixed with 20 mg DSPE-PEG2000 in chloroform. The DOX loaded DSPE-PEG2000
micelle was obtained under a stream of air form a thin film and hydrated with D.I
water. Consistent with previous reports, DOX entrapped in DSPE-PEG2000 micelles
showed a significantly improved cytotoxicity (Figure 3.3.4.1B) 58, equivalent to that
of amphiphilic DOX in vitro. The enhanced cytotoxicity correlated with enhanced
uptake (Figure 3.3.4.1A) 58. However, after 4h incubation, the capsulated DOX
were observed to be primarily accumulated in the nuclei which indicates the
release of unmodified DOX(Figure 3.3.4.1C)

58.

These results proved that the

intracellular trafficking of amphiphilic DOX is not the same as DOX entrapped in
polymeric micelles.
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Figure 3.3.4.2 Design of pH sensitive amphiphilic DOX, and its intracellular
distribution and cytotoxicity. 58 (A) Amphiphilic NHNH-DOX was synthesized by
conjugating of doxorubicin hydrochloride (DOX) to DSPE-PEG2000-NHNH2. (B)
B16F10 cells at the density of 1× 105 cells per well were seeded to a 6-wells plate
for overnight. Cells were treated with DOX loaded DSPE-PEG2000 micelles and
MitoTracker Green for mitochondria tracking whereas cell nuclei(blue) were
stained with DAPI. Scale bar = 10 µm. (C) In vitro cytotoxicity of free DOX,
amphiphilic DOX and amphiphilic NHNH-DOX against B16F10 cells 24 h. B16F10
cells at the density of 5 × 105 were incubated with either amphiphilic DOX or free
doxorubicin with varying concentrations for 24h. Cell proliferation was evaluated
by AlamarBlue assay.
The sorting of lipids is a process of central importance in cellular
transportation pathways. Intracellular rearrangement of lipid has been proposed
to be mediated by a physical mechanism based on the coordinating between
intracellular membranal composition and cell membrane transport curvatures. To
address whether the lipid sorting of diacyl lipid PEG transported DOX to
mitochondria, we constructed the same amphiphilic DOX conjugation but through
a pH sensitive hydrazone linkage (amphiphilic NHNH-DOX) (Figure 3.3.4.2A) 58.
As the hydrazone linkage between the PEG units and drug (DOX) is liable to
hydrolysis in low pH environment, the releasing of DOX happens in the acidic
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condition of the endosomal/lysosomal intracellular compartments after the
amphiphilic NHNH -DOX internalization, thereby providing a clear demonstration
of the act of amphiphilic lipid motif and free doxorubicin drug (Figure 3.3.4.2B) 58.
In this case, DOX fluorescence in nuclei as well as in mitochondria was observed.
The mitochondria accumulation of this pH-sensitive amphiphilic DOX might be the
incomplete cleavage of hydrazone bond under endosomal pH. Another possibility
is that cargos transported via caveolae-dependent route are delivered to
caveosomes instead of lysosomes. Along this route, the pH is maintained neutral
and no degradative substrate is appeared. Nevertheless, the partial nuclear
accumulation of amphiphilic hydrazone-DOX strongly suggest that DOX is not
released in our original amphiphilic DOX (non-cleavable) design. To compare the
anti-proliferation efficacy of DOX from amphiphilic DOX is released with not
releasable, cell was treated with either amphiphilic DOX (amphiphilic DOX) or pHsensitive amphiphilic DOX(amphiphilic NHNH-DOX). After 24 hours, we observed
slightly enhanced cytotoxicity, indicating in our case, release free DOX promoted
the cytotoxic efficacy (Figure 3.3.4.2C) 58. However, amphiphilic DOX selectively
accumulating in mitochondria is still unique and superior in novelty and functions.
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3.3.5 Albumin is not engaged as a participant of the intracellular sorting of
amphiphilic DOX.

Figure 3.3.5.1 Influence of serum on amphiphilic DOX uptake and distribution.
58 B16F10 cells at the density of 1× 105 cells per well were seeded to a 6-wells
plate at 37 °C. After overnight adhesion, cell medium was removed and replaced
with 0% FBS and 10% FBS medium with DOX and amphiphilic DOX at a final
concentration of 1.0 µM for 4 hours. Cells were treated with free DOX, and
amphiphilic DOX. Cell nuclei and mitochondria were tracked by DAPI (blue) and
MitoTracker, respectively. Scale bar = 5 µm.58
Albumin is reported to be engulfed by cells via endocytosis pathway.
Degraded in lysosomal compartment of cells is the termination of the fate of
albumin. The exact mechanism is few discussed, since albumin is such a
ubiquitous molecule that any experimental setting trying to mimic the mechanism
of its uptake pathway is supposed to be very difficult. To explore the effect of
albumin on albumin containing on intracellular accumulation and distribution in
vitro, the B16F10 cells uptake of free DOX and amphiphilic DOX in complete cell
growth medium (10% fetal bovine serum, FBS) and FBS-free medium were
examined by confocal microscope (Figure 3.3.5.1).
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Figure 3.3.5.2 Subcellular location of amphiphilic DOX/ bovine serum
albumin (BSA). 58 Bovine serum albumin-Alexa 660 (BSA-Alexa 660) were preincubated with amphiphilic DOX in PBS (pH 7.4) for 4 h at 37 °C. B16F10 cells
seeded on the a 6-wells plated were incubated with BSA/amphiphilic DOX complex
for 4 h amphiphilic DOX (1.0 μM) in FBS free cell culture medium.
As discussed in Chapter 2, at first two hours, uptake of amphiphilic DOX
showed negatively correlated with FBS content in vitro, reflecting the shift of
equilibrium lay to the direction of cellular membrane insertion at low albumin
concentrations (Figure 2.3.5.2A and B) 58. However, after twelve hours incubation,
parity between cellular uptake and albumin binding was observed for amphiphilic
DOX in the various of FBS content (the major protein in FBS is albumin) in B16F10
cells (Figure 2.3.5.2C) 58. At low content of albumin, amphiphilic DOX equilibrated
between albumin/drug complex status and cell anchoring status (Figure 2.3.4.2)
58.

The coexistence of these status jointly promotes intracellular uptake compared

than free DOX. However, in physical environment the blood albumin concentration
(35–50 g/L) is ~ 10 times higher than that in cell culture medium (<4.5 g/L), leading
to albumin binding be a majority. Natheless, amphiphilic DOX retained in the
mitochondria even without presence of FBS in cell culture medium (Figure 3.3.5.1)
58,

suggesting albumin is not participate in the intracellular trafficking of amphiphilic

DOX,

and

that

the

intracellular

release

of

amphiphilic

DOX

from

albumin/amphiphilic DOX complex in biomembranes before lipid sorting is highly
possible.
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To further demonstrate the albumin/drug complex is degraded before lipid
sorting process and albumin is not participate in tracking of amphiphilic DOX,
amphiphilic DOX/ bovine serum albumin (BSA, 1:1 in molar ratio) complex were
incubated with B16F10 cells for 4 hours in FBS free cell culture medium at 37 °C.
After that, cells were stained with DAPI and analyzed by CLSM. While preincubated with BSA, amphiphilic DOX was partially occupied by cells showing the
incomplete co-localization between BSA and amphiphilic DOX (Figure 3.3.5.1).37,
68

These results demonstrated that in vitro, albumin competes with cells to

amphiphilic DOX conjugation and not engage as a participant of the intracellular
sorting of amphiphilic DOX.
3.3.6 Amphiphilic modification is not a universal strategy for mitochondria
drug delivering.
In this study, amphiphilic modification via diacyl lipid poly(oxyethylene) is
considered to the essence for mitochondria target. To investigate whether it can
be a universal strategy for mitochondria-specific targeting, we modified fluorescein
with the same amphiphilic groups and tracking its internalization. In B16F10 cells,
the intracellular uptake of amphiphilic fluorescein was further colocalized with
mitochondria tracker and investigated using confocal microscopy. Interestingly,
distinct with amphiphilic DOX, no mitochondrial retention of amphiphilic fluorescein
was observed (Figure 3.3.6.1). These results indicated that amphiphilic
conjugation would not be a universal strategy for the mitochondrial targeting and
need to be discussed case by case.
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Figure 3.3.6.1 Structure of amphiphilic fluorescein and its intracellular
distribution.58 B16F10 cells were incubated with amphiphilic Fluorescein for 24 h
and imaged to detect its intracellular distribution.
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Figure 3.3.6.2 Subcellular location of Cholesterol-PEG2000-DOX at 4 h. 58
B16F10 cells at the density of 1× 105 cells per well were seeded on cover glasses
in 6-wells plates for adhesion. Cells were treated with Cholesterol-PEG2000-DOX
for 4 h. Cell nuclei and mitochondria were tracked by DAPI (blue) and Mito-Tracker,
respectively. Scale bar = 5 µm.
To determine whether DOX is an indispensable portion in the amphiphilic
mitochondria targeting drug, we conjugated DOX to another lipid poly(oxyethylene),
cholesterol-PEG2000. Unlike diacyl lipid poly(oxyethylene) which is anionic,
cholesterol is in electric neutrality and more hydrophilic. CLSM images showed
that, cholesterol-PEG2000-DOX accumulated in mitochondria (Figure 3.3.6.2),
which was identical to amphiphilic DOX. Correlation coefficient analysis between
green and red colors was performed in triplicate and showed strong colocalization
(Pearson coefficient, 0.547, 0.57 and 0.59; Manders coefficient, 0.909/0.848,
0.938874/0.872 and 0.822/0.955992), which suggested similar results with
amphiphilic DOX. These data indicated that amphiphilic modification on DOX
played a leading role on altering its internalized destination. And the lipid structural
requirement for mitochondrial accumulation can tolerant the transformation on
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amphiphilic property to some extent. This observation schematized that the unique
mitochondrial targeting property was under the particular combination between
amphiphilic lipid and doxorubicin, resulting from its chemical and biophysical
peculiarity
However, currently, we are not able to give a full explanation of the detail
structure-function relationship (e.g. whether PEG plays a role). It appears the
amphiphiles and DOX contributed jointly to the overall physicochemical
characteristics which govern the mitochondria targeting. Perhaps amphiphilic
modification alters the overall hydrophilic/hydrophobic balance of DOX and
subsequently affect its permeability, diffusion, and membrane partition. Another
hypothesis is that mitochondria need fatty acid as a high energy source for the cell
195.

Together, these results clearly demonstrated that in vitro, amphiphilic

modification on DOX enhanced the cellular uptake and selectively targeted DOX
to mitochondria.
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3.3.7 Amphiphilic DOX generates massive reactive oxygen species (ROS) in
mitochondria.

Figure 3.3.7.1 Amphiphilic DOX generated reactive oxygen species (ROS) in
cellular mitochondria. 58 (A) B16F10 cells were incubated with 10 µM DOX and
amphiphilic DOX for 4h. After drug treated, ROS generation was quantified by a
ROS indicator, H2DCFDA (DCF, green) which was incubated with cells at a final
concentration of 20 μM for 30 min. Scale bar of CLSM is 10 µm. (B) Flow cytometer
quantification of ROS generation was assigned in B16F10 cells treated with DOX
or amphiphilic DOX at the final concentration at 1, 5 and 10 μM. 58
The action mechanism of doxorubicin is known primarily by DNA
intercalation to disrupt topoisomerase-II-mediated DNA repair

196.

DOX-induced

reactive oxygen species (ROS) generation leads to oxidative damage of
mitochondria functions or endoplasmic reticulum stress via in vitro has been
reported to be another mechanism

197.

To address the source and potential

mechanism of action of amphiphilic DOX, we analyzed the production and
intracellular location of ROS using the ROS indicator (H2DCFDA, 2’,7’dichlorodihydrofluorescein diacetate probe). The kinetic and dose-dependent
studies between ROS generation and drug concentration were performed (Figure
3.3.7.1). ROS generation was dominantly coincided with amphiphilic DOX on
CLSM analysis demonstrating the amphiphilic DOX was responsible for ROS
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production (Figure 3.3.7.1A). Flow cytometry analysis indicated that the ROS
generation compliance with the presence of amphiphilic DOX in a dose-dependent
manner (Figure 3.3.7.1B). Since the colocalization between amphiphilic DOX and
ROS source, it is well-documented to deduce that ROS response in mitochondria,
which locations of amphiphilic DOX, induced tumor cell damage and death.
Together, these data set a certification to amphiphilic DOX as a promising
chemotherapy approach, which significantly increased anti-cancer potency,
through effective delivery and recruiting DOX to mitochondria and induce DOXrelated cytotoxicity inside of tumor cells.
3.3.8 Amphiphilic DOX achieves tumoral -mitochondrial targeting in vivo.

Figure 3.3.8.1 Amphiphilic DOX achieved dual target in vivo. 58 Melanoma
tumor bearing mice were injected with doxorubicin hydrochloride, or amphiphilic
DOX, or PBS. All groups (n = 8) of mice received above treatments (5 mg/kg
equivalent doxorubicin, 10 μL/g of the body weight) on days 5, 8 and 11 by
intravenous injection in the lateral tail vein. At the end of experimental period,
tumor tissues were isolated, frozen and sliced in to sections. Mitochondria and cell
nuclei were stained with MITO-ID RED and DAPI. Scale bar = 10 μm.
Mitochondria are special subcellular components that play a key role in
mediation of essential cellular metabolism including lipid metabolism, adenosine
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triphosphate (ATP) production and apoptosis activation.

153-154

Delivery of drug to

mitochondria may bypass the classical resistance pathways, however, no
mitochondria-targeting pharmaceutical formulations have been approved clinically.
That is because in cancer chemotherapy, a successful mitochondrial delivery
requires multi-levels of targeting: it must achieve sufficient circulating time in blood
for drug exposure, and must achieve tumor tissue- and tumor cell-specific
accumulation followed by mitochondria-specific accumulation.35, 158-164 To inspect
whether amphiphilic DOX could achieve such multi-level target and terminate in
tumor mitochondria in vivo, tumor tissues were isolated at the end of experiment.
After frozen, sectioned, and labeled with a mitochondria-selective dye (MITO-ID),
samples were analyzed by CLSM. As displayed in Figure 3.3.8.158, delivery of
amphiphilic DOX was observed in tumor tissue mitochondria showing the strong
red color fluorescence coincidence with green color. In contrast, under the same
conditions, fluorescence signal of free DOX in the tumor section was undetectable.
These results demonstrated that amphiphilic DOX could surmount multiple
physiological barriers and terminated at tumor mitochondria in vivo.
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3.4 Conclusions.
Following the approaches and discussion in chapter 2, we investigated
pharmacokinetics / pharmacodynamics of amphiphilic DOX in this chapter. In vivo
tumor model results demonstrated that amphiphilic DOX can surmount multiple
physiological barriers and terminated at tumor mitochondria. This is achieved by
molecular engineering which functionalizes doxorubicin with an amphiphilic diacyl
lipid connected by a PEG spacer. This functionalized modification fulfills a dual
objective: first, amphiphilic DOX reaches and penetrates solid tumor by
“hitchhiking” on albumin protein

198-200.

Albumin-binding enhances the molecular

size of doxorubicin and prolongs its circulating time in the blood

199.

In addition,

albumin-binding facilitate delivery of DOX drug in the tumor by the enhanced
permeation and retention (EPR) effect and more importantly, by active metabolic
uptake because tumors heavily use albumin as an energy and nutrient source 198199.

Compared with mice treated with free DOX, injection of amphiphilic DOX

accumulated heavily in tumor but not in heart. Second, amphiphilic DOX retained
in mitochondria following tumor cell uptake both in vitro and in vivo. Efficient
mitochondria targeting with amphiphilic DOX led to a significant increase in
oxidative stress in tumor mitochondria, resulting in markedly improved antitumor
efficacy. We explored the mechanism of cellular entrance as well as mitochondrial
target in vitro. Albumin/ drug complex transported into cells via multiple pathway at
the first step, following albumin degradation and drug exposure. Due to the
particularly chemical and physical properties, amphiphilic DOX accumulate in
mitochondria area after lipid sorting. However, the mechanism needs to be further

94

investigated. Thus, in vivo, amphiphilic functionalization improves the doxorubicin
molecule’s physicochemical properties, which in turn re-defines its bioavailability,
organ and subcellular distributions. Amphiphilic modification represents a simple,
effective, and nontoxic molecular.
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Chapter 4. Enhancing Antigen Presentation and Inducing Antigen-Specific
Immune Tolerance with Amphiphilic Peptides.
4.1 Introduction.
In response to an unknown trigger, autoimmune diseases proceed when
the immune system begins producing responses that attack hosts’ own tissues
instead of fighting infections.201 There are more than eighty types of autoimmune
diseases, including type 1 diabetes (T1D), systemic lupus erythematosus (lupus),
inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) 202-203. Numerous
researches in developing targeted immune therapies for autoimmune disease
during the past decades led to an improved range of choice for clinical treatment.
However, the majority of medical treatment approved by the Food and Drug
Administration (FDA) have focused on the nonspecific immune suppression of
immune inflammatory activity.203 Relative side effects and occasions of global
immunosuppressive of those drugs are not conductive to long-term patients
survival.204 The aim of current researches in immune tolerance is to develop the
disease-specific treatments to maintain the immune system to delete autoantigens
and autoreactive immune cells without the deleterious effects of immune system.
Peptide specific therapy takes advantages of other forms of therapy because
without antigen process activities, it can response to the desired pathogenic
epitopes, limiting the possibility for hyperactivation of immune systems. Therefore,
the use of desired peptides combined with adjuvants provide a potent strategy to
specifically induce tolerance or drive the immune response towards an antiinflammatory cytokine profile.
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4.1.1 Type 1 diabetes(T1D) and peptide therapy.
Type 1 diabetes (T1D) is one of the most studies chronic autoimmune
disorders in the last two decades. A conventional therapy such as insulin
replacement alleviates the symptoms of hyperglycemia but cannot cure the
mellitus. An alternative therapy that transplanting islets cells from health donor is
limited by several drawbacks such as the availability of islets cells, and the
requirement for lifelong immunosuppression. 203, 205-208
Peptide-specific immunotherapy has emerged as a potent approach to
prevent T1D and an important support in understanding of the immune
tolerance.209-215 Initiated by the presentation of self-antigens, T1D has been
associated with autoreactive T cells destruction of insulin-producing beta(β)-cells
within pancreatic islets. Antigen fragments or peptides triggering autoimmune
disorders are generated by the degradation of self-antigen inside the by antigenpresentation cells (APCs).216 The recognition process of autoreactive T cells
depends on the presence in the APCs of major histocompatibility complex (MHC)
proteins, which bind such peptides, display them on the cell surface, and present
them there, along with a co-stimulatory signal, to the T cells. Indeed, the
autoreactive T cells are fully activated and provided proliferative and survival
signals by both the stimulation of the T-cell receptor (TCR) by MHC and costimulatory receptors through costimulatory molecules. There are two structurally
and functionally distinct types of MHC proteins: MHC class I proteins, which
present peptides to CD8 cytotoxic T cells, and MHC class II proteins, which present
foreign peptides to CD4 T helper cells.205, 210, 212, 215
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Control antigen-specific autoreactive T cell and induction antigen-specific
immune tolerance to β-cell by administration of insulin protein or insulin fragments
has been reported to prevent non-obese diabetic (NOD) mice from developing
T1D.206-207 NOD mice express rearranged diabetogenic TCR genes and
spontaneously develop T1D, characterized by the autoreactive T cell mediated
response of the insulitis and eventually destruction of the pancreatic β-cells. Direct
immunization of NOD mice with β-cell associated peptides causes a large
percentage deletion of the autoreactive T cell. Importantly, the administration of
soluble peptides treated diabetic active T cell increase the percent of T1D free
NOD mice, suggesting that high-affinity peptide of autoimmune epitopes might be
a potential therapeutic modulator in autoimmune disease.217-220
4.1.2 Autoantigen presentation plays a key role in triggering peripheral
tolerance of T1D.
In peptide immunotherapy, peptide degraded from autoantigen and
presentation by MHC are essential for induction and maintenance of peripheral
immune tolerance. The differentiation and proliferation of T cells in the lymphoid
tissues are regulated by the antigen and co-stimulatory molecules displayed by
APCs and environmental cytokines.219 The challenges in peptide therapy of T1D
are 1) soluble therapeutic peptides introduced parenterally maintain a short halflife and cannot efficiently reach LN where the antigen presentation initiated, 2)
soluble therapeutic peptides possess low affinity to MHC complex leading to the
poorly presenting to T cell. Low level of the antigen presentation and transitorily
peptide displayed on the APCs in the lymph nodes (LNs) limit the efficacy in
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regulating autoreactive T cells and activating regulatory T cells (Tregs) so that fail
in restore immune tolerance.
In NOD mice, the initiating diabetogenic epitope insulin B chain 9-23 (B923) peptide binds weakly (with micromolar affinity and rapid dissociation rate) to
IAg7

217-220

, demonstrated by the weak simulation of diabetogenic T cells

responding to wildtype insulin B9-23 peptides presented by APCs in vitro

221-223.

Thus, quantitatively and qualitatively insufficient antigen presentation leads to
immunological ‘ignorance’ to autoantigens and represents one of the major hurdles
in current antigen specific immunotherapy. Several approaches are currently being
tested to enhance autoantigen presentation to induce antigen-specific tolerance.
For example, autoantigen delivered by nanoparticles224-227 or antibodies

228-229

which target dendritic cells (DCs), the most efficient APCs, to enhance the antigen
uptake, processing, and presentation. Efficient delivery of antigens to DCs in the
absence of costimulatory stimuli promoted tolerance induction in murine model of
T1D.

225

Antigen co-delivered with small-molecular drugs which modulate the DC

function is another popular approach for prophylactic and therapeutic vaccines that
can drive antigenic tolerance.

227

Recently, targeting DCs in the LNs and

modulating DC-T cell interactions have been shown to be a viable approach to
restoring T1D tolerance.51 LNs house abundant DCs/lymphocytes and are the
primary anatomic sites where the inflammatory/regulatory fate of T cell polarization
is determined.230 For example, intralymphatic injection of glutamic acid
decaroboxylase (GAD65), another major autoantigen in T1D has led to
dramatically prolonged preservation of β-cell function as compared to
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subcutaneous injection in clinical study, due to the enhanced antigen presentation
to T cells in the LNs.51 Another intriguing approach to increase the presentation of
the low-affinity antigens is to use alternative antigen ligands. For example, peptide
ligands

containing

pathogenic

epitopes

obtained

by

post

translational

modifications of insulin peptide on the C-terminal (neoantigen) induced potent
antigen-specific tolerance in NOD mice.231 These modifications increased the
stability of binding of peptide on the C-terminus MHC anchor amino acid residue.231
Likewise, infusion of small amounts of insulin B9-23 mimetope modifying the MHC
anchor residue at position 9 from an arginine to a glutamic acid (R22E) completely
prevented the onset of T1D in NOD mice.223 These important studies
demonstrated that efficient antigen presentation under subimmunogenic
conditions is indispensable in tolerance induction in vivo.
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4.2 Method.
4.2.1 Materials.
Dexamethasone (DEX), methotrexate (MTX) and mycophenolic acid
(Myco),

4-dimethylaminopyridine

(DMAP),

succinic

anhydride,

dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), dimethyl sulfoxide
(DMSO), chloroform, triethylamine (TEA) were purchased from Sigma-Aldrich (St.
Louis,

MO).

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-

[amino(polyethylene glycol)-2000] (DSPE-PEG2000-NH2) and 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPEPEG2000- Maleimide) were purchased from Laysan Bio Inc. (Arab, AL) HPV-16
E749-57

peptide

(CRAHYNIVTE),

(CISQAVHAAHAEINEAGR), Cysteine B

OVA

323-339

Cysteine

peptide

9-23(CSHLVEALALVCGERG),

OVA-

derived peptide SIINFEKL (CSIINFEKL) were custom synthesized by GenScript
(Piscataway, NJ). Lipo-G2-CpG were synthesized in house using an ABI 394
DNA/RNA synthesizer. 232 Murine MHC class I tetramers were obtained from MBL
international Corporation (Woburn, MA). Antibodies were purchased from
eBioscience (San Diego, CA) or BD Bioscience (San Jose, CA).
4.2.2 Cells and animals.
Mouse bone marrow dendritic cells (BMDCs) were generated as described
by a modified protocol.233 Cells were cultured in complete medium (MEM, 10%
fetal bovine serum (Greiner Bio-one), 100 U/mL penicillin G sodium and 100 μg/mL
streptomycin (Pen/Strep). Animals were housed in the United States Department
of Agriculture (USDA)-inspected Wayne State University animal facility under
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federal, state, local and NIH guidelines for animal care. Female C57BL/6 mice (58 weeks), NOD/ShiLtJ mice (5 weeks) and OT-II mice were obtained from the
Jackson Laboratory.
4.2.3 Preparation and purification of amphiphilic antagonists.
For amphiphilic dexamethasone (amphiphilic DEX), dexamethasone (1.0 g,
2.54 mmol), succinic anhydride (0.51 g, 5.10 mmol) and DMAP (0.155g, 1.27 mmol)
were dissolved in acetone. After reaction for 12 hours, the solvent was evaporated
under reduced pressure. The product (DEX-succinic acid) was re-dissolved in
ethanol/ water mixture (0.6% v/v) and recrystallized. The while solid product (DEXsuccinic acid) was further dried using oil pump. DEX-succinic acid (1.1 g, 2.23
mmol) was dissolved in 50mL acetone and activated by DCC (0.55 g, 2.67 mmol)
and NHS (0.37 g, 3.21 mmol). The product (DEX-succinic-NHS) in filtrate solution
was obtained by filtration after overnight reaction. DEX-succinic-NHS compound
was dried under reduced pressure. Amphiphilic DEX conjugated was produced by
coupling DEX-succinic-NHS (25 mg, 0.043 mmol) to the DSPE-PEG2000-amine
(100 mg, 0.036 mmol) in DMSO (3.5 mL) and TEA (2.5 µL). After overnight
coupling, amphiphilic DEX was purified by HPLC with a reverse-phase C4 column,
lyophilized and dissolve in DMSO.
For amphiphilic methotrexate (amphiphilic MTX), methotrexate (0.5 g, 1.56
mmol) was dissolved in 10 mL chloroform and activated using DCC (0.37 g, 1.87
mmol) and NHS (0.22 g, 1.87 mmol). MTX-NHS was concentrated by air dry after
overnight reaction. Amphiphilic MTX conjugated was produced by reacting MTXNHS (25 mg, 0.033 mmol) to the DSPE-PEG2000-amine (100 mg, 0.036 mmol) in
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chloroform (2 mL) and TEA (2.5 µL). After overnight coupling, Amphiphilic MTX
was purified by HPLC with a reverse-phase C4 column, lyophilized and redissolved in chloroform.
For amphiphilic Mycophenolic acid (amphiphilic Myco), Mycophenolic acid
(0.1 g, 0.22 mmol) was dissolved in 2 mL DMSO and activated by DCC (0.055 g,
0.27 mmol) and NHS (0.03 g, 0.26 mmol). Myco-NHS was concentrated by air dry
after overnight reaction. Amphiphilic Myco conjugated was produced by coupling
Myco-NHS (25 mg, 0.040 mmol) to the DSPE-PEG2000-amine (100 mg, 0.036
mmol) in DMSO (2 mL) and TEA (2.5 µL). After overnight coupling, Amphiphilic
Myco was purified by HPLC with a reverse-phase C4 column, lyophilized and
dissolve in DMSO.
4.2.4 Preparation and purification of amphiphilic peptides.
5 mg peptides was mixed with two equivalent DSPE-PEG2000-Maleimide in
1 mL DMF with additional 3 µL triethylamine (TEA). After stirred in the dark at room
temperature (RT) for overnight, the DMSO solvent was removed in a stream of air
for 72 h to as much as possible. The product residues were re-dissolved in 5 mL
D.I water for HPLC purification. Amphiphilic peptides were purified by a C4
reverse-phase HPLC column (Thermo Scientific, 250 x 4.6 mm, 5 µm).
4.2.5 In vitro characterization.
The cellular uptake of unmodified peptides and amphiphilic peptide was
quantified in B16F10 cells by flow cytometry (Applied Biosystems). Cells with a
density of 1 × 106 cells per well were seeded to 96-wells plates for overnight. The
cell medium was removed and replaced with fluorescein labeled peptide and
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amphiphilic peptide at a final concentration of 1.0 µM for 2 hours. Following
washed three times with 1 × PBS, cells were harvested in FACS and analyzed by
Attune acoustic focusing cytometer. Each assay was performed in triplicate.
For characterization of subcellular location, cells (104 cells per well) were
seeded on a coverslip in a 6-wells plate. For visualization amphiphilic peptide, cells
were then incubated with fluorescein labeled peptide or amphiphilic peptide at the
concentration of 1 μM at 37 °C. After 4 hours’ incubation, the cells were washed
with 1 × PBS, fixed in 3% paraformaldehyde (PFA) and washed with PBS three
times. Imagines were captured by Zeiss confocal (LSM 780) microscope with a 63
× oil-immersion objective.
4.2.6 Electrophoretic mobility shift assay (EMSA).
An agarose gel (0.7%) electrophoresis mobility shift assay was used to
detect the interaction between albumin with lipo-peptide. The solution of
fluorescein labeled free OVA323-339 and lipo-OVA323-339 were incubated with Fetal
Bovine Serum (FBS) (estimate molar ratio 1:1) for 4 hours at 37 °C. Samples were
loaded for electrophoresis run under 75 V for 30 min. Images were recorded using
a digital camera (Canon) under UV illustration for fluorescein labeled peptide, or
briefly stained with Coomassie blue for protein characterization.
4.2.7 Lymph nodes draining and cellular uptake.
The study was approved by the division of laboratory animal resources
(DLAR) and animals were cared in the DLAR animal facility under federal, state,
local, and NIH guidelines for animal care. 3.3 nmol of fluorescein labeled free
OVA323-339 or amphiphilic OVA323- 339 were subcutaneously (s.c.) administrated in
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the tail base of C57BL/6 mice (n=4 LNs/group). After 24 h drug administration,
treated mice were euthanasia using carbon dioxide. Inguinal and axillary lymph
nodes were next isolated and digested with 1.5 mL freshly prepared enzyme
solution in RPMI-1640 medium consisted of collagenase/ dispase (0.8 mg/mL,
Sigma-Aldrich) and deoxyribonuclease (DNase, 0.1 mg/mL, Sigma-Aldrich).
Lymph nodes cells were extracted and stained with anti-CD11c antibody.
Percentages of peptide positive cells among the CD11c positive in the lymph
nodes were quantified by flow cytometry.
4.2.8 Ex vivo antigen presentation assay.
A round-bottom 96-wells plate were seeded with BMDCs (7 days after
isolation). Cells were pulsed with different concentrations of OVA 323-339 or lipoOVA323-339 peptides for 2 hours. Cells were then washed and cocultured with
freshly isolated OT-II CD4+ T cells (DC/T cell ratio 1:2) for 48 hours. Supernatant
was transferred and stored at -80 °C prior to IL-2 quantification by ELISA assays.
All experiments were performed in triplicate. In some cases, BMDCs were fixed
with 1% PFA at room temperature for 30 min, or treated with NH4Cl (200 μM) at
37 °C in culture medium for 45 min.
4.2.9 In vivo tolerization with amphiphilic peptide.
On day 0, C57BL/6 mice at the age of 6-8 weeks (n = 3) were immunized
with ovalbumin protein (OVA,10 μg) and lipo-CpG (1.24 nmol) and tolerized with
OVA323-339 (10 μg) or amphiphilic OVA323-339 on days 7 and 17. On day 21, mice
were challenged with ovalbumin (10 μg) and lipo-CpG (1.24 nmol). The antigenspecific cellular and humoral immune response were evaluated on day 28. Vaccine
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injections were performed s.c. at the base of the tail with the volume of 100
µL/animal.
4.2.10 In vivo tolerization with amphiphilic antagonists and antigen.
On day 0, C57BL/6 mice at the age of 6-8 weeks (n = 3) were stimulated
with ovalbumin protein (10 μg) and lipo-CpG (1.24 nmol) and tolerized with
antagonists or amphiphilic antagonists (10 µg) mixed with ovalbumin (10 μg) on
days 7 and 17. On day 21, mice were challenged with Ovalbumin (10 μg) and lipoG2-CpG (1.24 nmol). The antigen-specific cellular and humoral immune response
were evaluated on day 28. Vaccine injections were performed s.c. at the base of
the tail with the volume of 100 µL/animal.
4.2.11 Antigen-specificity study for amphiphilic antagonists.
On day 0 and day 14, C57BL/6 mice (6-8 weeks; n = 4 per group) were
stimulated with ovalbumin protein (10 μg) and lipo-CpG (1.24 nmol) at the left tail
side and tolerized with HPV peptide(10µg) and antagonists or amphiphilic
antagonists at the right tail side. On day 21, antigen-specific cellular immune
responses were evaluated. Vaccine injections were performed s.c. at the base of
the tail with the volume of 100 µL/animal.
4.2.12 Antigen-specific cytotoxic T lymphocyte (CTL) detection.
OVA-specific CD8+ T cells were detection by tetramer assay. Seven days
after vaccinal boost, blood samples (100 µL) were collected and lysed by ACK
lysing buffer twice. White blood cells were next blocked with Fc-blocker (antimouse CD16/CD32 monoclonal antibody). Blocked cells were further incubated
with phycoerythrin (PE)-labeled SIINFEKL/Kb tetramer and (allophycocyanin) APC
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labeled anti-CD8 antibody (ebioscience) for 30 minutes at room temperature. After
washed and resuspended in flow cytometry staining buffer (FACS buffer, 1% w/v
BSA in PBS), cells were analyzed using flow cytometer. OVA-specific CD8+ T cells
were gated on living, APC and PE positive group.
4.2.13 Intracellular cytokine staining.
Lysed cells from blood were pulsed with peptide antigen for 6 hours at 37 °C
in T-cell expansion medium (RPMI 1640, 10% v/v fetal bovine serum (FBS), 1 mM
HEPES, 50 μM β-mecaptoethanol(BME), 100 U/mL Penn/Strep, 1 mM sodium
pyruvate, 1x MEM non-essential amino acids solution), with additional autophagy
inhibitor brefeldin A for 4 hours. After stimulation, intracellular staining for IFN-γ
secreting CD4 T cells was performed according to previous protocol234. Cells were
incubated with APC labeled anti-CD4 antibody and then fixed and permeabilized
using fixation and permeabilization solutions (BD Biosciences). Foxp3 staining
was performed according to the manufacturer’s instructions (Ebioscience) for
fixation and permeabilization.
4.2.14 Enzyme-linked immunosorbent assay (ELISA).
Serum or cell culture supernatant levels of antibodies and cytokines were
determined by Enzyme-linked immunosorbent assay (ELISA). ELISA plates were
coated with capture antibodies in PBS for overnight. On the next day, coated plates
were blocked with 1% BSA solution for at least 1 h. A series of dilutions of serum
samples were then added and incubate for 1h. Plates were washed with three
times and horseradish peroxidase (HRP) conjugated goat anti-mouse IgG was
added at 1 μg/ml for 30 min. After washed three times with PBS/1% Tween 20
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solution, plates were added with 3,3’,5,5’-Tetramethylbenzidine (TMB) for color
developing. Finally, 1 M H2SO4 stop solution were added and the absorbance was
read at 450 and 570 nm as the reference using a plate reader.
4.2.15 Monitoring blood glucose levels.
Blood glucose of NOD mice was monitored with glucose meters (Accu‐
Check III) twice a weekly during the experimental period. Diabetes was defined as
two subsequent blood glucose values over 300 mg/100 mL.
4.2.16 Statistical analysis.
Statistical analysis the mean values of two groups were performed using
unpaired Student’s t tests. The statistical difference between groups were
determined using a one-way analysis of variance

20

with Bonferroni post-test. All

the values were expressed as means ± standard error of mean. GraphPad Prism
(San Diego, CA) software was used for all the statistical analyses. ***p < 0.001,
**p < 0.01, *p < 0.05. NS, not significant.
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4.3 Results and discussions.
Lymph nodes (LNs) are essential for the functioning of the adaptive immune
system, including initiating and resolving immune response as well as maintaining
tolerance235. Antigen presenting cells (APCs) such as dendritic cells (DC)
presenting antigen to T lymphocytes are initiating and maturing in LNs. Recently,
we reported an ‘albumin-hitchhiking’ approach which self-deliver vaccine subunit
to antigen presenting cells in the draining lymph nodes. The self-delivery strategy
was achieved by the molecular design of amphiphilic molecules that hijack the
traffic pathway of endogenous albumin in the lymphocytic interstitial fluid

235.

To

test whether this approach can be translated to deliver small molecular anti-agonist
or peptide for immune regulation, we conjugated anti-agonists: dexamethasone
(DEX), methotrexate (MTX) and mycophenolic acid (Myco) and CD4 epitope
peptide OVA323-339, an ovalbumin derived, MHC II restricted peptide to the
amphiphilic lipid, DSPE-PEG2000, following our previously published procedure.
4.3.1 Synthesis of amphiphilic antagonists.
The coupling of antagonists with amphiphilic motif were performed using a
primary amine/NHS ester chemistry. The schematic diagram and chemical formula
of every components are shown in Figure 4.3.1.1. Subsequently, products were
purified by reverse phase high performance liquid chromatography (HPLC).
Unconjugated antagonists were separated from amphiphilic antagonists after
applying the one-step gradient (0-100% of methanol) HPLC purification. The
presence of products was monitored through the absorption at 260 nm.
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Amphiphilic DEX, MTX and Myco were collected during 18 to 19.5 min, 19 to 20
min, and 19 to 20 min, respectively.

Figure 4.3.1.1 Schematic diagram and chemical formula of DEX, amphiphilic
DEX, MTX, amphiphilic MTX, Myco and amphiphilic Myco. Synthesis
procedures are dropped in the method part. Briefly, DEX was firstly coupled with
succinic anhydride. The DEX-succinic acid was further activated by NHS and
conjugated to DSPE-PEG2000-amine. The MTX and Myco was pre-activated with
NHS and coupled to DSPE-PEG2000-amine directly.
4.3.2 Synthesis of amphiphilic peptides.
The schematic diagram and chemical formula of amphiphilic peptides (lipopeptide) was shown in Figure 4.3.2.1, HPV-16 E749-57 peptide (CRAHYNIVTE),
OVA

323-339

cysteine

peptide

(CISQAVHAAHAEINEAGR),

cysteine

B9-23

(CSHLVEALALVCGERG) and OVA-derived peptide SIINFEKL (CSIINFEKL) at Nterminal.
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Figure 4.3.2.1 Schematic diagram of amphiphilic peptides. Synthesis
procedures are dropped in the method part. Briefly, peptides with amino-terminal
cysteines and DSPE-PEG2000-Maleimide were dissolved in dimethylformamide
(DMF) and agitated at room temperature for 24 hours, following the addition of
triethylamine (TEA) for their coupling.
4.3.3 Amphiphilic antagonists downregulate the expression of CD40, CD80.
Dendritic cells (DCs) in lymphocytic systems can initiate both antigenspecific adaptative immune response or tolerance.236 The administration of a
stimulus for maturation switches DC function from tolerance to immunity, including
the development of CD4+T helper cells and activation cytolytic CD8+ T cells. Costimulatory signals (for example, CD40/80) and cytokines (e.g. TNF-α) are
necessary to induce a strong antigen-specific CTL response.236 To determine the
efficiency of amphiphilic antagonists to inhibit DCs maturation, we stimulated
murine bone marrow BMDCs from C57BL/6J mice with CpG which is the TLR9
ligand and can enhance DC maturation and induce high-level expression of CD40
and CD80. BMDCs cultured with granulocyte–macrophage colony-stimulating
factor (GM-CSF) for 6 days were stimulated with CpG ODNs in the presence or
absence of anti-agonists. Flow cytometry analysis indicated DC cells cultured with
CpG increased the expression of CD80 and CD40. Pre-treated of 10 nM
amphiphilic antagonists or free drugs resulted in inhibition of CD40 but not CD80
expression compared with only CpG-treated cells (Figure 4.3.3.1). Specifically,
both inhibitory expression in CD40 and CD80 were observed in MTX and
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amphiphilic MTX treated cells (Figure 4.3.3.1 C, D). However, there was no
significant difference between both amphiphilic drugs and the free drugs treated
groups.

Figure 4.3.3.1 Amphiphilic antagonists downregulated the expression of
CD40, CD80. 3 DCs were incubated with DEX (10 nM) and CpG (1 nM), or
amphiphilic DEX (10 nM) and CpG (1 nM), or CpG (1nM) only, or medium (No
treatment) alone for 24 h. Expression of the membrane markers CD80 (A and C)
and CD40 (B and D) were assessed by flow cytometric analysis. Data shown the
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mean values ± SEM. *,p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001 by
one-way ANOVA with Bonferroni post-test.

Figure 4.3.3.2 Amphiphilic antagonists inhibited TNF-α production in vitro.
(A-C) DCs harvested on day 6 were incubated for 24 hours with various
concentration of antagonists or their amphiphilic conjugation and CpG (1 nM), CpG
(1 nM) only, or medium (No treatment) alone. At the end of the incubation,
supernatants were analyzed by ELISA for TNF-α content.
It is reported that DC maturation with tumour necrosis factor (TNF)-α upregulates surface MHC and costimulatory molecules.237-238 To determine the
efficiency of amphiphilic antagonists on inhibiting maturation of DCs triggered by
CpG, we assessed the production of TNF-α cytokine. The BMDC were pre-treated
with varies concentration of antagonists and stimulated with CpG. Free DEX
treatment resulted in inhibition of cytokine secretion and situated at 1 nM, whereas

113

amphiphilic DEX showed a dose-dependent inhibition of TNF-α production (Figure
4.3.3.2A). Free MTX exhibit inhibition only in a high drug concentration and its
amphiphilic conjugation showed almost the same level with CpG only, indicating
lack of inhibitory effects (Figure 4.3.3.2B). Although, the MTX were less effective
in control the TNF-a production, regarding of downregulatory of CD40 and CD80
receptors (Figure 4.3.3.1B), it was still a candidate for further study. Moreover,
TNF-α secreting were suppressed by low concentration of free Myco but high
concentration of amphiphilic Myco. (Figure 4.3.3.2C).
4.3.4 Immunosuppression with amphiphilic antagonists in vivo.
To evaluate the efficacy of the tolerization using amphiphilic antagonists in
vivo, we firstly quantified the OVA-specific CD8+ T cells after immunization. Briefly,
animals were immunized subcutaneously on day 0 with premixture of 10 µg
ovalbumin (OVA)

239

protein and 1.25 nmol lipo-G2-CpG which is a potent LNs

targeting adjuvant and stimulates toll-like receptor 9.35 On the 7, mice randomly
separated into eight groups were initially tolerized with soluble mixture of 10 µg
OVA and 10 µg antagonists or their amphiphilic conjugation. On day 14, animals
were tolerization with double dose (20 µg OVA and 20 µg antagonists or their
amphiphilic conjugation). Mice were finally challenged on day 21 with OVA and
lipo-G2-CpG. The percentage of OVA-specific CD8+ T cell proliferation in
peripheral blood was quantified on day 28 to determine the cellular immunity. As
we reported before, lipo-G2-CpG adjuvant induced relatively robust antigenspecific CD8+ T cell responses, showing more than 25% OVA-specific CD8+ T
cells in blood35 (Figure 4.3.4.1B, C, D). Decreased percent of antigen-specific T
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cell were observed by antagonists or OVA treatment (Figure 4.3.4.1B, C, D),
showing a reduced percent of OVA specific CD8+ T cells and, therefore indicating
induction antigen-specific immunosuppressive. Unexpectedly, the opposite trends
were observed in groups whose mice treated with an antagonists or amphiphilic
antagonists admixed with OVA protein. Mice administration with mixture of
antagonists or their amphiphilic conjugation with OVA antigen did not showed a
synergistic

immunosuppressive

effect,

even

compensated

contribution from OVA protein (Figure 4.3.4.1B, C, D).

the

inhibitory
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Figure 4.3.4.1 Amphiphilic antagonists or antigen alone induced
immunosuppression in the cytotoxicity T cell response. (A) Mice were
immunized with 10ug OVA protein and 1.25nmol lipo-G2-CpG at day 0. Mice were
received s.c. immunizations with 10 μg OVA and 10ug free antagonists or
amphiphilic conjugation on day 7 and double dose on day 14. (B-D) Mice were
sacrificed (SAC) and blood was collected 7 days post challenge and assayed for
cytotoxicity OVA-specific CD8+ T cell.
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Figure 4.3.4.2 Amphiphilic antagonists or antigen alone induced
immunosuppression in humoral response. Blood was collected 7 days post
challenge and assayed for ELISA. The IgG titers were defined as the half maximal
effective dose (EC50) of a 4-parameter logistic (4PL) curve fit curve.
Peripheral antibody response gives insight into the humoral immunity. 240 To
investigate the capacity of amphiphilic antagonists on development humoral
immune tolerance, the level of OVA-specific IgG tolerization with amphiphilic
antagonists were evaluated. Animals were immunized subcutaneously with an
admix of lipo-G2-CpG and OVA on day 0 and successive two tolerization with
amphiphilic antagonists or their free drugs with or without OVA protein. Seven
days after stimulating with OVA and lipo-G2-CpG on day 20, sera were isolated
from mice for antibody response analysis. Mice without treatment showed a
crescent antibody response with mounting anti-OVA titers. Compared with no
treatment, the group treated with OVA protein showed suppressive the anti-OVA
antigen response (Figure 4.3.4.2). However, the inhibitory effect on humoral
response was weakened by the antagonists, as providing all the co-administration
groups had enhanced anti-OVA IgG titers comparing with OVA group (Figure
4.3.4.2). These results suggested that administration of amphiphilic antagonists
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and their parental drugs inducted the activation of T-cell and humoral immunity and
pre-mix of antigen and adjuvants are critical.
4.3.5 Study of antigen-specific immune tolerance
To test whether the specificity of the immunosuppressive effects of
antagonists is broad and systemic, animals were injected (subcutaneously) with
mixture of amphiphilic human papillomaviridae (HPV-16 E749-57) peptide,
antagonists or amphiphilic antagonists and lipo-G2-CpG were injected in the left
limb and OVA protein plus lipo-G2-CpG were administrated in the right limbs
(Figure. 4.3.5.1A). Mice immunized with amphiphilic HPV only did not broadly
induce OVA specific CD8+ T-cell responses indicating the antigen specificity.
Mixing amphiphilic HPV peptide with DEX and amphiphilic DEX completely
blocked the development of HPV specific CD8+ T-cell responses. At the same time,
amphiphilic DEX had no effect on the OVA-specific response initiated in the
contralateral limb, whereas the inhibitory effect was observed in the free DEX
group (Figure. 4.3.5.1B and C). Injection of either MTX or Myco or their
amphiphilic conjugation had no significant effect on the response to either HPV or
OVA epitope (Figure. 4.3.5.1B and C).
amphiphilic

HPV

peptide

with

As a summary, co-immunization

antagonists

did

not

show

a

universal

immunosuppressive effect (Figure. 4.3.5.1 B, C) and the mode of action and
pathway of every antagonists need to be addressed. On the other hand, these
results encouraged us to explore amphiphilic peptides instead of amphiphilic
antagonists as a vaccine to induce immune tolerance.
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Figure 4.3.5.1 Treatment with amphiphilic antagonists did not result in broad
immunosuppression. (A) Mice were immunized with OVA and lipo-G2-CpG in the
right limbs and with anti-agonists or amphiphilic antagonists with amphiphilic HPV
peptide and lipo-G2-CpG in the left limbs twice on day 0 and day 14. (B and C)
HPV-specific CD8+ T cells (B) and OVA-specific CD8+ T cells (C) were isolated
from blood seven-days post the vaccination boost.
4.3.6 Immunosuppression with amphiphilic peptides.
IFN-γ secreting from T helper cells was a critical cytokine for T cell
proliferation and an important activator of APCs.241 To investigate whether
amphiphilic peptides can inhibit T-cell activation under inflammatory conditions,
animals were immunized with OVA protein combined with lipo-G2-CpG on day 0.
Mice were tolerized twice with 10 μg MHC class II-restricted OVA323–339 peptide
and its amphiphilic conjugation (on N-terminal) on day 7 and day 14. The final
challenge with OVA protein and lipo-G2-CpG was performed on day 21 (Figure
4.3.6.1A).
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Figure
4.3.6.1
Amphiphilic
peptides
induction
antigen-specific
immunological tolerance. (A) One week after immunized with OVA protein mixed
with lipo-G2-CpG, animals were separated into two subgroups and tolerized with
10 μg dominant MHC-II peptide (OVA323-339) vaccine, or lipo-OVA323-339,
respectively. (B-D) Blood was collected 7 days post immunological challenge and
assayed for IFN-γ secreting CD4+ T cell (B), CD4+ CD25+ Foxp3+ Treg cells (C)
and anti-OVA IgG responses (D).
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Both free OVA323-339 peptide and amphiphilic OVA323-339 peptide reduced the
frequency of peripheral IFN-γ producing CD4+ T cell (Figure 4.3.6.1B). Moreover,
a significantly inhibition of CD4+ IFN-γ+ T cell was observed in mice treated with
lipo-OVA323-339, as compared to those with soluble OVA323-339 (Figure 4.3.6.1B).
Mice tolerization with amphiphilic OVA323-339 also substantially attenuated antigen
responses against OVA showing decreasing anti-OVA IgG titers compared with
non-tolerized treatment group as well as free peptide group (Figure 4.3.6.1D).
Regulatory T cells (Tregs) are a subset of immunosuppressive T cell that have a
major role in mediating the activity of self-reactive cells.3, 242 To investigate if the
amphiphilic peptides can restore autoreactive regulatory mechanism, the CD4 +
CD25+ Foxp3+ from mice blood were quantified on day 28. An enhancement in the
percentage of CD4+ CD25+ Foxp3+ T cells in the blood was distinct after lipoOVA323-339 treatment (Figure 4.3.6.1C), indicating induction of T regulatory cells.
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Figure 4.3.6.2 Immunization with lipo-OVA323-339 deleted OT-II T cells and
promoted the induction of regulatory T cells. (A-C) CD4+ OT-II T cells labeled
with CFSE and were i.v. transferred into C57BL/6 mice on day -1. At day 0, animal
received s.c. immunizations with PBS (no treatment), ovalbumin protein (OVA, 10
μg), OVA323-339 peptide (10 μg), or amphiphilic OVA323-339 (equal amount peptide).
Six days later, inguinal nodes were harvested and the frequencies of OT-II T cells
(B) as well as the percentage of Foxp3+CD25+CD4+ T cells were quantified(C) (n
= 3 per group).
Animals from Figure 4.3.6.1 immunized with amphiphilic peptide
conjugation that had shown a long-lasting inhibition of T helper cells and anti-OVA
responses with promoting regulatory T cells. To further demonstrate the lipoOVA323-339 can efficiently promote T reg and restore immune tolerance, the
carboxyfluorescein succinimidyl ester (CFSE)-labeled OTII CD4+ T cells (CD45.1+)
were adoptively transferred into CD45.2+ mice. Six days after administration of 10
μg of OVA or OVA323-330 or lipo-OVA323-330 peptide, the proliferation of the OTII
CD4+ Foxp3+ T cells were measured using flow cytometry (Figure 4.3.6.2A).
Lymphocytic and splenic OTII T-cell proliferation, determined by dilution of the
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fluorophore CFSE as measured by flow cytometry (Figure 4.3.6.2B) were
decreased in mice treated with amphiphilic OVA323-330 compared with OVA protein
or peptide. OTII CD4+ Foxp3+ T cells were markedly enhanced in mice
administrated lipo-OVA323-330 (Figure 4.3.6.2C) demonstrating that amphiphilic
conjugation increased antigen-specific Treg priming compared with the soluble
antigen.
4.3.7 Amphiphilic peptide antigen binds albumin, accumulates in the antigen
presenting cells in the draining lymph nodes.
To determine whether this approach can bind with albumin, fluorescein
labeled free peptide and lipo-OVA323-339 were developed. We firstly validated lipoOVA323-339 binding to fetal bovine serum (FBS) and the interaction between lipopeptide and albumin was visualized by electrophoretic mobility shift assay. 243 FBS
showed a major albumin band visible after Coomassie staining (Figure 4.3.7.1A,
lane 5). OVA323-339 peptides (Figure 4.3.7.1A, lane 1) and its amphiphilic
conjugation (Figure 4.3.7.1A, lane 3) were analyzed by native gel electrophoresis.
FBS showed a major albumin band visible after Coomassie staining (Figure
4.3.7.1A, lane 5). The avidity of lipo-OVA323-339 to albumin was confirmed by
(Figure 4.3.7.1A, lane 3-5), showing a short-haul fluorescent band visible under
UV co-migrated with pure albumin as compared with lipo-OVA323-339. In contrast,
OVA323-339 incubated with FBS showed no changes in relative mobility (Figure
4.3.7.1A, lane 1 and 2), indicating a lack of interaction with albumin.
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Figure 4.3.7.1 Albumin-binding lipo-peptide remarkedly increased LNs
drainage and DCs uptake. (A) Fluorescein labeled lipo-OVA323-339, or OVA323-339
were incubated with FBS at 37 °C for 4 hours and analyzed by native gel
electrophoresis (0.8% agarose). The peptide bands were visualized by photograph
under UV; protein bands were stained with Coomassie blue. (B) Fluorescein
labeled peptides were injected s.c. at the tail base (n = 4 LNs/group), inguinal and
axillary nodes were isolated 24 h after injection and analyzed by flow cytometry.
Next, we validated lipo-OVA323-339 uptake in LNs following subcutaneously
administration into animals at tail base (n = 4 LNs per group). Inguinal and axillary
LNs were excised 24h following injection of either OVA323-339-FAM or lipo-OVA323339-FAM

confirmed the mounting LNs accumulation. As shown in Figure 4.3.7.1B,
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albumin-binding lipo-OVA323-339 exhibited dramatically increased accumulation in
DCs in both inguinal nodes and axillary nodes. By contrast, negligible amount of
unmodified OVA323-339 was detected in DCs in the lymph nodes.
4.3.8 Amphiphilic peptide antigen anchors on cell membrane and increase
the interaction between peptide and major histocompatibility complex (MHC)
complex.
Animals from Figure 4.3.7.1 had shown an inhibition of anti-OVA responses
and CD4 T helper cells were immunized and boosted with lipo-OVA323-339. Major
histocompatibility complex (MHC) binds protein fragments derived from infectious
microorganism or agents and displays them for recognition by the miscellaneous
T cells.41-43 Antigen specific CD4+ T cells are reported to compete for access to the
peptide-MHC class II complex on the APCs. OVA323-339 peptide can be directly
displayed by MHC II complex and present to CD4 + T cells by APCs.244-247 In this
study, we hypothesized that lipo-OVA323-339 interacts with MHC II by a heterobivalent interaction: the peptide moiety binds to MHC-II while the lipid tail anchors
the peptide on DC membrane (Figure 4.3.8.1C). We firstly investigated the uptake
and biodistribution in vitro of amphiphilic peptide on bone marrow dendritic cells
(BMDCs) which containing unmatured APCs. CLSM results showed amphiphilic
peptide colocalization to the cell membrane equatorial periphery (Figure 4.3.8.1A),
indicating a significant portion of the peptide anchored on the membrane surface.
Compared with unmodified peptide, flow cytometric analysis of lipo-OVA323-339
treated cells exhibited a 10-fold increase in DC uptake (Figure 4.3.8.1B) and
demonstrated binding to be in a high affinity.
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Figure 4.3.8.1 Enhanced interaction of peptide to MHC complex expressed
on cell surface of DCs. (A and B) Confocal images (A) and uptake quantifications
(B) of BMDCs after 1h incubation with fluorescence dye labeled OVA323-339 (A, left)
or lipo-OVA323-339 (A, right) showing red color on cell membrane equatorial
periphery. (C) Schematic illustration showing CD4 lipo-peptide anchors on the cell
surface and directly loads onto MHC-II. Unmodified peptide displays transient
interaction (low affinity and short half-live) with MHC, resulting in insufficient
presentation to T cells (upper panel). In contrast, membrane anchored peptide acts
as an antigen reservoir, enhancing the binding and presentation via an additional
association with cell membrane. Membrane-anchor enables rebind as peptide and
MHC disengage (lower panel). Scale bar = 20 μm.
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4.3.9 Membrane anchored amphiphilic peptide enhances the antigen
presentation.

Figure 4.3.9.1 Amphiphilic OVA323-339 peptide recognized CD4 epitope and
can be presented to T cells without antigen processing. (A and B) BMDCs pretreated with NH4Cl, or fixed with paraformaldehyde (PFA), were pulsed with low
dose of 2 μg/mL (A) or high dose of 10 μg/mL lipo-OVA323-339 (B) or unmodified
OVA323-339 for 2 h. OT-II T cells were then added and co-cultured for 48 h. IL-2
production were quantified by ELISA measurement of IL-2 production. Data show
the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001
by unpaired student’s t-test.
Next, we explored the ability of lipo-OVA323-339 vaccine to enhance MHC
class II antigen presentation by ex vivo antigen presentation assay.248-249 To
suppress the interference, BMDCs were pre-treated with NH4Cl, or fixed with
paraformaldehyde (PFA) for 30 min, washed, and pulsed with (2 μg/mL or 10
µg/mL) lipo-OVA323-339 or the same amount of unmodified OVA323-339 for another 2
h. Interleukin-2 (IL-2) has a key role in immune system function as promotors of
effector T cells and memory T cells when the initial T cell is stimulated. 250-252 To
investigate the capacity of lipo-OVA323-339 bound DCs to stimulate OVA-specific
naive CD4+ T cells, IL-2 production was quantified by enzyme-linked
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immunosorbent assay (ELISA) measurement. As shown in Figure 4.3.9.1A, with
low concentration (2 µg/mL, unsaturated) GM-CSF induced BMDCs loaded with
lipo-OVA323-339 exhibited significantly enhanced activation of OT-II T cells
compared with unmodified OVA323-339. At higher peptide concentration (10 μg/mL)
(Figure 4.3.9.1B), IL-2 secreting induced by both lipo-OVA323-339 and unmodified
OVA323-339 activated OT-II T cells at similar level indicating the saturated binding
capacity. Resulting above suggested that amphiphilic modification did not disrupt
the bioactivity of the peptide, including binding epitopes and antigen presentation.

Figure 4.3.9.2 Amphiphilic OVA323-339 peptide enhanced antigen presentation
to T cells. (A) BMDCs were incubated with different concentrations of lipo-OVA323339, or unmodified OVA323-339, washed and co-cultured with OT-II T cells. IL-2 was
measured at 48 h. (B) BMDCs were pulsed with 10 μg/mL lipid-OVA323-339 or
unmodified OVA323-339 for 2 h, washed, and cultured for the indicated times to allow
peptide/MHC to decay. OT-II T cells were then added and co-cultured for another
48 h. T cell responses to DCs loaded with CD4 epitope were quantified by ELISA
measurement of IL-2 productions.
Lack of stability and ability on peptide interaction to MHC class II limited
antigen presentation and T cell differentiation.246-247 One of the critical challenges
on the peptides/ MHC II molecules interaction is that empty molecules quickly lose
the affinity to such peptides. Dosage, potency, and stability of peptide/MHC
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complex define a cumulative quantity of T cell receptor (TCR) stimulation that
governs the initial induction and persistence of peripheral T cell tolerance. 230, 253254

To assess the efficacy of membrane-anchored amphiphilic peptide on the

potency and duration of peptide presentation, BMDCs were pulsed with low
concentrations of lipo-OVA323-339, or soluble OVA323-339, washed and incubated
with OT-II T cells. Cell culture medium were collected at the different time point for
IL-2 measurement. Cells treated with lipo-OVA323-339 yielded an EC50 at 0.5ug/mL
which was 3-fold lower than that of unmodified OVA323-339 (1.5 μg/mL) (Figure
4.3.9.2A). The potency of peptide stimulation was significantly promoted by lipoOVA323-339.
To test whether membrane-anchored lipo-OVA323-339 can prolong the
antigen presentation, BMDCs were treated with 10 μg/mL (saturated) lipo-OVA323339

or equivalent amounts of free OVA323-339. Cell culture medium were then

removed and replace with fresh medium for various time periods during 24 h. OTII T cells were then added, and antigen presentation was determined by
quantification of IL-2 secretion following 48 h co-culture. Displaying of OVA323-339
peptide (t1/2 = 37 h) were sustainable showing 7-fold half-life extension in T-cell
stimulation, as compared to DCs pulsed with unmodified OVA 323-339(t1/2 = 5 h) in
equal amounts (Figure 4.3.9.2B). Due to the transit associating with MHC II, free
OVA323-339 resulted to 50% less IL-2 release by 5 h and lost >95% a day post
peptide incubating. These results indicated that treatment with amphiphilic peptide
can enhance peptide presentation to T cells through concentrating antigen
displayed on DCs as well as providing a unique hetero-bivalent interaction with
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MHC-II: the peptide moiety binds to MHC-II while the lipid tail anchors the peptide
on DC membrane.
4.3.10 Albumin-hitchhiking amphiphilic vaccines in animal models of Type 1
Diabetes (T1D).

Figure 4.3.10.1 Amphiphilic peptide vaccine protected mice from T-cell
induced autoimmune type 1 diabetes at the early period. (A-C) NOD mice
were treated with two (on week 6 and 8) s.c. injections of 20 µg B 9-23 peptide, LNtargeting B9-23 peptide (lipo- B9-23) or PBS, blood glucose concentrations were
monitored. (A) Percentage of diabetic mice (n = 12 for each group, p values were
shown by log-rank test). (B) At the age of week 10, percentage of IFN-γ secreting
CD4+ T cells and Foxp3+ CD25+ CD4+ T cells in blood. (C) At week 10, serum
cytokine levels were measured by ELISA.
Among the insulin epitopes recognized by non-obese diabetic (NOD) islet–
infiltrating T cells, insulin B chain amino acids 9 to 23 (insulin B: 9–23) is an
immunodominant T-cell target peptide that plays a central role in the disease
initiation.255-256 Subcutaneous injections of B9-23 peptide to NOD mice substantially
increased the threshold and reduced the incidence of diabetes, by controlling B 923

-specific Th1 inflammation responses (i.e., IFN-γ-producing) and inducing Th2

cellular responses.2, 257-258 To explore albumin-binding peptide-based deletion of
pathogenic T cells in an autoimmune model, we tested the ability of lipo-peptide
vaccine to prevent type 1 diabetes using non-obese diabetic mice model.
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Amphiphilic insulin B9-23 peptide was engineered implementation of our concept.
Tolerization with two dosing of free B9-23 or lpo-B9-23 at the week 6 and 8 of age,
the glucose level of mice was performed a long time tracking (>20 weeks) to allow
the vaccine to induce autoimmune diabetes. The occurrence of T1D of NOD mice
were developed spontaneously at week 12 and shared many symptomatic and
pathophysiological features of T1D. Mice treated with either B 9-23 peptide or
amphiphilic B9-23 peptide postponed the onset to week 13 and 16, respectively.
Flow cytometry analysis on blood lymphocyte at 10 weeks of age indicated that
treatment with lipo- B9-23 significantly reduced the percentage of B9-23 reactive CD4+
IFN-γ+ T lymphocytes after B9-23 peptide re-stimulation ex vivo and increased the
frequency of Foxp3 expressing regulatory T cells (Figure 4.3.10.1B). These
results suggested the lipo-B9-23 lowered the incidence of type 1 diabetes through
restoring immune tolerance and inhibiting auto-reactive T cell.
Cytokines are crucial mediators of the immune system and necessary for
process of the immune response. Interleukin 12 (IL-12) family

239, 259

are key

cytokines in the promotion of T cell responses which are required for the induction
of IFN-γ production and development of Th1 cells. On the contrary, transforming
growth factor-beta (TGF-β) is an immunosuppressive cytokine which regulates
immune response

260-262.

To further address the regulatory function and

demonstrate our hypothesis, IL-12 and TGF-β in peripheral blood serum were
quantified at the age of week 10 of NOD mice. ELISA analysis of blood cytokine
showed that following treatment with lipo- B9-23, inflammatory IL-12 production was
significantly reduced, whereas production of TGF-β was elevated (Figure
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4.3.10.1C), as compared to animals treated with PBS or unmodified B 9-23 peptide.
These results demonstrated that target peptide autoantigen to DCs in the draining
LNs via ‘albumin-hitchhiking’ supported the induction of tolerogenic mechanisms,
delaying the onset and reducing the incidence of T1D in NOD mice.
4.4 Conclusions.
Herein, we have discussed several approaches to restore immune
tolerance to prevention autoimmunity: 1) antagonists and its amphiphilic
conjugation treatment inhibited activation and proliferation of CTL and induce a
global immune tolerance. However, this inhibitory effect was compensated by
combination with antigen. 2) Lipid functionalization targets peptide antigen to DCs
in the LN by binding and trafficking with endogenous albumin after subcutaneous
injection. More importantly, lipid functionalization markedly enhanced peptide
presentation by a unique bivalent interaction with MHC II molecules on cell surface.
This approach might be applicable for diseases other than T1D, where efficient
antigen presentation is needed.
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Chapter 5. Conclusions and Future Perspectives.
Self-delivery drug amphiphiles represent a simple yet effective approach
designed to overcome the various biological barriers for drug delivery without the
need for exogenous carriers. The ability to program the molecular structures and
the physicochemical properties, which controls the interactions between the drug
amphiphiles and their biological surroundings has attracted significant research
interests. In fact, several of the drug amphiphiles have been approved by FDA and
more have reached the clinical testing stage. Despite tremendous progress made
in the field, many challenges remain. The delivery challenges include: 1) lack of
mechanisms for active targeting. Instead of ligand-receptor mediated targeting, the
drug amphiphiles accumulate in tumor or inflammatory tissues by passive targeting
(EPR effect)c, such passive targeting approach is limited due to the heterogeneous
nature of the diseases. The overall delivery efficiency of nanoparticle cancer drugs
(by EPR effect) is low—only a median of 0.7% of the injected dose retained in the
tumor. 2) lack of chemistry to precisely control the drug release. The linker design
must integrate the pharmaceutical performance, systemic stability, and overall
drug physicochemical properties. However, designing an ideal linker with all above
key attributes remains difficult, in many cases where the drugs need to be released,
premature or over-delayed release profiles are often observed. Additionally, the
structure and functional impacts of non-cleavable modification cannot be
overlooked; 3), lack of design mechanisms to guide the intracellular trafficking and
retention. Although lipids are constantly sorted and transported within the cells, the
exact trafficking mechanisms and specific organelle accumulation remains largely
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unknown. Drug conjugation further complicates the process because of the
intracellular protein binding and trafficking of drug molecule.
As we gain more knowledge toward the fundamental aspect of diseases,
new drug amphiphiles and novel design principles will emerge in the future. Next
generation drug amphiphiles are expected to overcome these challenges, enabling
structure-based rational design and optimization.
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ABSTRACT
SELF-DELIVERY DRUG AMPHIPHILIES IN CHEMOTHERAPY AND
IMMUNOTHERAPY
by
JINGCHAO XI
December 2019
Advisor: Dr. Haipeng Liu
Major: Chemical Engineering
Degree: Doctor of Philosophy

Eliminating the need for external delivery systems, self-delivery drug
amphiphiles represent a simple yet effective approach designed to overcome the
various biological barriers for drug delivery. The ability to program the molecular
structures and the physicochemical properties, which control the interactions
between the drug amphiphiles and their biological surroundings has attracted
significant research interests. In this work, we constructed several amphiphilic
drugs including chemotherapeutic and immunotherapeutic agents. These
amphiphiles exhibited interesting interactions with their biological surroundings.
Amphiphiles self-assemble into spherical micelle structures in aqueous solution.
However, in the presence of complexed biological fluids, they also possess a
strong affinity toward albumin protein and plasma membrane. By controlling the
molecular structures which govern the three-way equilibrium, self-delivery
drugs/vaccines overcoming multiple biological barriers were designed and tested
in vitro and in vivo. Employed endogenous albumin protein as a drug carrier, selfdelivery chemotherapeutic drug amphiphiles (e.g. amphiphilic doxorubicin) were
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firstly investigated. High levels of tumor-specific and extended circulating half-life
facilitated doxorubicin-induced cytotoxicity and anti-cancer efficacy. Importantly, it
was the first report on lipid-based targeting subcellular mitochondria which filled
the gap of intracellular tracking using lipoplex approaches. Translating from
albumin-based self-delivery strategy, amphiphilic lipid-based immunosuppressive
drugs and peptides were studies on several immune disease models. Amphiphilic
peptides were observed to accumulate in the antigen presenting cells (APCs) in
the lymph nodes (LNs), enhance the potency and duration of peptide antigen
presentation by APCs, and induce antigen-specific immune tolerance that
controlled both T-cell- and B-cell-mediated immunity. Moreover, immunization with
an amphiphilic insulin B chain 9-23 peptide, an immunodominant CD4+ T cell
epitope in non-obese diabetic (NOD) mice successfully restored antigen-specific
immune tolerance delaying the onset of Type 1 Diabetes (T1Ds). Overall, those
self-delivery amphiphilic drugs provided a simple approach to improve the
bioavailability, bioaccessibility, and biocompatibility of the pharmaceutical
payloads, which will be emerged as a novel design principle for drug delivery in
the future.
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